<?xml version="1.0" encoding="UTF-8"?>
<rr:ResultsReport xmlns:rr="http://integration.foundationmedicine.com/reporting" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd">
  <rr:CustomerInformation>
    <rr:ReferenceID>01-2023-00029850</rr:ReferenceID>
    <rr:CSN />
    <rr:TRF>ORD-1640275-01</rr:TRF>
    <rr:MRN>49496051</rr:MRN>
    <rr:PhysicianId>109266</rr:PhysicianId>
    <rr:NPI />
  </rr:CustomerInformation>
  <rr:ResultsPayload>
    <FinalReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" StagingId="1327787" clinicalId="1329134" xsi:noNamespaceSchemaLocation="http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd">
      <Application>
        <ApplicationSettings>
          <ApplicationSetting>
            <Name>Statement</Name>
            <Value />
          </ApplicationSetting>
        </ApplicationSettings>
      </Application>
      <DemographicCorrectionDate />
      <ReportId>ORD-1640275-01</ReportId>
      <SampleName>US1564901.01</SampleName>
      <Version>0</Version>
      <Sample>
        <FM_Id>ORD-1640275-01</FM_Id>
        <SampleId>US1564901.01</SampleId>
        <BlockId>S112-21816 A (PF23070)</BlockId>
        <TRFNumber>ORD-1640275-01</TRFNumber>
        <TestType>FoundationOne CDX</TestType>
        <SpecFormat>Slide Deck</SpecFormat>
        <ReceivedDate>2023-05-30</ReceivedDate>
        <processSites>
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="Extracted DNA" />
          <processSite address="150 Second St., 1st Floor, Cambridge, MA 02141" cliaNumber="22D2027531" locationID="1" locationName="Cambridge" processID="1" processName="LC" />
        </processSites>
      </Sample>
      <PMI>
        <ReportId>ORD-1640275-01</ReportId>
        <MRN>49496051</MRN>
        <FullName>Kao Liu, Chin Yun</FullName>
        <FirstName>Chin Yun</FirstName>
        <LastName>Kao Liu</LastName>
        <SubmittedDiagnosis>Brain glioblastoma (GBM)</SubmittedDiagnosis>
        <Gender>Female</Gender>
        <DOB>1961-01-15</DOB>
        <OrderingMD>Yeh, Yi-Chen</OrderingMD>
        <OrderingMDId>109266</OrderingMDId>
        <Pathologist>Not Provided</Pathologist>
        <CopiedPhysician1 />
        <MedFacilName>Taipei Veterans General Hospital</MedFacilName>
        <MedFacilID>205872</MedFacilID>
        <SpecSite>Brain</SpecSite>
        <CollDate>2023-05-15</CollDate>
        <ReceivedDate>2023-05-30</ReceivedDate>
        <CountryOfOrigin>TW</CountryOfOrigin>
      </PMI>
      <PertinentNegatives>
        <PertinentNegative>
          <Gene>IDH1</Gene>
        </PertinentNegative>
        <PertinentNegative>
          <Gene>PDGFRA</Gene>
        </PertinentNegative>
      </PertinentNegatives>
      <Summaries alterationCount="22" clinicalTrialCount="18" resistiveCount="0" sensitizingCount="5" />
      <VariantProperties>
        <VariantProperty geneName="ABL1" isVUS="true" variantName="P901A" />
        <VariantProperty geneName="APC" isVUS="true" variantName="E129Q" />
        <VariantProperty geneName="BRCA2" isVUS="true" variantName="V2109I" />
        <VariantProperty geneName="BRD4" isVUS="true" variantName="V228I" />
        <VariantProperty geneName="DAXX" isVUS="true" variantName="E457del" />
        <VariantProperty geneName="GATA6" isVUS="true" variantName="A221T" />
        <VariantProperty geneName="JAK3" isVUS="true" variantName="P745L" />
        <VariantProperty geneName="KMT2D (MLL2)" isVUS="true" variantName="T5464M" />
        <VariantProperty geneName="MEF2B" isVUS="true" variantName="P272T" />
        <VariantProperty geneName="MYCN" isVUS="true" variantName="A184S" />
        <VariantProperty geneName="NTRK1" isVUS="true" variantName="R161H" />
        <VariantProperty geneName="TEK" isVUS="true" variantName="Y1024F" />
      </VariantProperties>
      <priorTests />
      <Genes>
        <Gene>
          <Name>EGFR</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>G598V</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="1.6" isEquivocal="false" name="G598V" />
              </AlterationProperties>
              <Interpretation>EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). Amplification of EGFR has been associated with increased expression of EGFR mRNA and protein in several cancer types (Liang et al., 2010; 20637128, Bhargava et al., 2005; 15920544, Yang et al., 2012; 22490401). A mutation of the EGFR gene, referred to as EGFRvIII, results from a gene rearrangement that deletes exons 2-7. This alteration causes an in-frame deletion of 801 base pairs encoding part of the extracellular ligand-binding domain (Nishikawa et al., 1994; 8052651). This deletion has shown to result in ligand-independent (constitutive) phosphorylation and activation of EGFR, as well as consequent tumorigenesis (Nishikawa et al., 1994; 8052651, Nedergaard et al., 2012; 22385404). EGFR mutations that have been characterized in biochemical assays to be activating, as observed here, are predicted to confer sensitivity to EGFR-targeted therapies (Foster et al., 2010; 20942962, Cai et al., 2008; 18193092, Stabile et al., 2005; 15735034, Zhang et al., 2006; 17409930, Siegfried et al., 2012; 22258476, ManChon et al., 2014; 24743239, Cho et al., 2014; 24894453, Hama et al., 2009; 19726454, Tam et al., 2009; 19671738, Kancha et al., 2009; 19147750, Chen et al., 2006; 16205628, Lee et al., 2006; 17177598, Ymer et al., 2011; 24212795, Razis et al., 2009; 19789313, Wang et al., 2011; 21532887, Cai et al., 2008; 18193092, Kim et al., 2019; 31290142, Sueangoen et al., 2020; 32190291, Lundby et al., 2019; 31585087). Across several genomic studies of CNS tumors, EGFR amplification has been reported in 16.9% of anaplastic astrocytomas, and 39.7% of glioblastoma multiformes (GBMs)(Jonsson et al., 2019; 31263031, Brennan et al., 2013; 24120142, Ceccarelli et al., 2016; 26824661, Thomas et al., 2017; 28472509). EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors (cbio-Jonsson et al., 2019; 31263031, cbio-Brennan et al., 2013; 24120142, cbio-Ceccarelli et al., 2016; 26824661, cbio-Thomas et al., 2017; 28472509). In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10-15% of cases and approximately half have a low-level amplification of the mutated allele (Lee et al., 2006; 17177598, Vivanco et al., 2012; 22588883). In a study of IDH-wildtype GBM samples, EGFR alterations were detected in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event (Yan et al. 2020; DOI:10.1200/PO.19.00385). The EGFRvIII mutation has been variously reported in 6-46% of GBM samples (Nishikawa et al., 1994; 8052651, Shinojima et al., 2003; 14583498, Nishikawa et al., 2004; 15700833, Mellinghoff et al., 2005; 16282176, Viana-Pereira et al., 2008; 18507036, Yoshimoto et al., 2008; 18223223, Larysz et al., 2011; 21455841, Verhaak et al., 2010; 20129251, Lv et al., 2012; 22752145). No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM (Srividya et al., 2010; 20702468, Das et al., 2011; 20888234); however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM (Smith et al., 2001; 11504770). The link between EGFRvIII status and prognosis is unclear, although some studies suggest that it may be linked to improved survival and response to chemotherapy (Montano et al., 2011; 22241957). In multiple glioblastoma (GBM) studies, the presence of EGFRvIII has not predicted clinical benefit from first-generation EGFR TKIs such as erlotinib (Van den Bent et al., 2009; 19204207, Haas-Kogen et al., 2005; 15956649, Brown et al., 2008; 18955445, Preusser et al., 2008; 18458820, Wen et al., 2014; 24470557, Gallego et al., 2013; 24352766) or gefitinib (Rich et al. 2004; 14638850, Uhm et al., 2011; 20510539, Preusser et al., 2008; 18458820). However, case reports have described patients with EGFRvIII-positive GBM responding to erlotinib (Doyle et al., 2018; 30410775, D'Alessandris et al., 2013; 23132371, Custodio and Perez-Segura, 2010; 20462843, D'Alessandris et al., 2018; 30306271). In a retrospective study of patients with GBM treated with erlotinib or gefitinib, co-expression of EGFRvIII with PTEN protein was the strongest predictor of response (P&lt;0.001)(Mellinghoff et al., 2005; 16282176), suggesting that activity in this setting is dependent on PTEN status (Mellinghoff et al., 2007; 17255257, Arif et al., 2018; 29492119). However, a prospective Phase 2 trial testing erlotinib monotherapy for patients with EGFRvIII and PTEN-positive recurrent glioblastoma reported minimal efficacy and was terminated (Gallego et al., 2013; 24352766). The second-generation EGFR TKIs afatinib and dacomitinib have shown minimal efficacy for patients with EGFRvIII glioblastoma (GBM)(Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602, Sepulveda-Sanchez et al., 2017; 28575464, Chi et al., 2020; 32923886). A Phase 1/2 study of afatinib, temozolomide, or the combination for patients with GBM reported clinical benefit, including for patients with EGFRvIII; however, temozolomide alone and in combination exhibited better responses than afatinib monotherapy (Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602). A Phase 2 trial of dacomitinib for patients with EGFR-amplified GBM reported a DCR of 26% (5/19) among patients with EGFR amplification and EGFRvIII; however, the trial failed to meet its primary endpoint of 6-month PFS (Sepulveda-Sanchez et al., 2017; 28575464). A retrospective biomarker analysis of another Phase 2 study of dacomitinib for patients with GBM found no association between EGFRvIII and clinical benefit (Chi et al., 2020; 32923886). Patients with glioma and co-occurring EGFR amplification and EGFRvIII have reported responses to osimertinib (Cardona et al., 2021; 34498213, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). However, a patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFRvIII, experienced progression of the EGFRvIII-positive tumor during treatment with osimertinib (Makhlin et al., 2019; 31769726). On the basis of preclinical data, osimertinib inhibits EGFRvIIII-driven tumor growth in vitro (Chagoya et al., 2020; 32547705, Gao et al., 2021; 33910930). A single-center Phase 2 pilot study for EGFR-amplified solid tumors (n=13) reported 1 PR and 2 SDs, including 1 with a 9-month duration, for the 8 evaluable patients with glioblastoma (Byeon et al., 2020; 32107712). Novel approaches that specifically target EGFRvIII in glioblastoma (GBM), such as the vaccine rindopepimut, are under investigation in both clinical and preclinical studies. A Phase 2 trial reported significant improvement in OS for patients with EGFRvIII-positive GBM with rindopepimut in combination with bevacizumab compared to bevacizumab alone (HR=0.53, p=0.01)(Reardon et al., 2020; 32034072). However, a Phase 3 study of rindopepimut combined with temozolomide compared to temozolomide alone in newly diagnosed EGFRvIII-positive GBM patients was terminated after the interim analysis, due to a lack of clinical benefit as measured by OS (20 vs. 20 months)(Weller et al., 2017; 28844499). For patients with non-small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR–TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao-Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao-Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with EGFR-mutated bithalamic glioma have reported responses to osimertinib (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses (Mondal et al., 2020; 32303840). On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib (Mondal et al., 2020; 32303840). Clinical studies of the second-generation EGFR TKIs afatinib and dacomitinib for patients with EGFR-amplified gliomas have shown limited efficacy (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886, Reardon et al., 2015; 25140039, Blumenthal et al., 2016; 27531351); however, a small subset of patients has experienced clinical benefit (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886). Multiple studies have failed to find a positive association between increased EGFR expression and clinical benefit from erlotinib or gefitinib for patients with glioblastoma (Mellinghoff et al., 2005; 16282176, Franceschi et al., 2007; 17353924, Chakravarti et al., 2013; 23182702, Hegi et al., 2011; 21471286, Rich et al. 2004; 14638850). There are conflicting data on the efficacy of anti-EGFR antibodies for the treatment of EGFR-amplified tumors. A meta-analysis of colorectal cancer patients treated with second-line or higher cetuximab or panitumumab observed an association between EGFR copy number gain and increased OS and PFS (Jiang et al., 2013; 23441167). However, studies of patients with head and neck squamous cell carcinoma or gastric cancer found either no association or a negative association between EGFR copy number gain and survival after treatment with first-line cetuximab or panitumumab in combination with chemotherapy (Licitra et al., 2011; 21048039, Smyth et al., 2020; 33199443). The Phase 3 INTELLANCE trial of depatuxizumab mafodotin (ABT-414), an EGFR-targeted antibody-drug conjugate with a toxic payload, in patients with EGFR-amplified glioblastoma (GBM) was stopped for futility. Interim analysis demonstrated improved median PFS (mPFS) of ABT-414 monotherapy compared with placebo (HR=0.84); however, no OS benefit was observed (HR=1.01). Improved mPFS was also observed in patients harboring EGFRvIII (HR=0.73) but without an OS improvement (HR=0.95) (Lassman et al., 2019; Neuro-Oncology Abstract ACTR-21). The Phase 2 INTELLANCE trial demonstrated clinical benefit for EGFR-amplified GBM for the combination of ABT-414, temozolomide, and radiotherapy (HR=0.66, p=0.017), but there was no evidence of efficacy for ABT-414 monotherapy (HR=1.04, p=0.83)(Bent et al., 2020; 31747009). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2022) (Louis et al., 2021; 34185076).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cetuximab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 trial of cetuximab with the anti-VEGF monoclonal antibody bevacizumab for patients with glioblastoma (GBM) did not show improved efficacy compared with bevacizumab alone (Hasselbalch et al., 2010; 20406901). However, another Phase 2 study demonstrated that for patients with GBM harboring EGFR amplification but lacking expression of the EGFRvIII variant, treatment with cetuximab resulted in significantly longer PFS and numerical (although not statistically significant) improvement in OS (Lv et al., 2012; 22752145). In addition, a case report for an EGFR-amplified patient with GBM treated with cetuximab using intraarterial cerebral infusion (SIACI) in combination with chemotherapy reported a stable response without recurrence at 6 months (Kulason et al., 2018; 29790314). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Panitumumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1 trial of EnGeneIC delivery vehicle (EDV) targeting EGFR with panitumumab in combination with doxorubicin for 14 patients with glioblastoma (GBM) reported no responses and 28% (4/14) SDs (Whittle et al., 2015; 26279503). Panitumumab has shown efficacy as monotherapy or in combination with chemotherapy for patients with KRAS-wildtype colorectal cancer (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858) and has been investigated in a variety of other tumor types. For patients with head and neck squamous cell carcinoma (HNSCC), data are conflicting; some trials of panitumumab in various lines and with different chemotherapy combinations have shown modest benefit (Vermorken et al., 2013; 23746666, Wirth et al., 2010; 19892746, Siano et al., 2017; 28592616) and others have reported no benefit (Mesia et al., 2015; 25596660, Giralt et al., 2015; 25596659, Siu et al., 2016; 27930762). A Phase 3 study of chemotherapy with or without panitumumab for patients with advanced gastroesophageal cancer was terminated for futility (Waddell et al., 2013; 23594787). Trials in a variety of tumor types have failed to show significant benefit for patients, including non-small cell lung cancer (NSCLC) (Crawford et al., 2013; 24389433, Shuette et al., 2015; 26094080); biliary tract cancers, including cholangiocarcinoma (Leone et al., 2016; 26540314, Vogel et al., 2018; 29413685); and renal cell carcinoma (RCC) (Rowinsky et al., 2004; 15210739). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Osimertinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-mutated glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677) and additional clinical studies suggesting clinical benefit for these patients (Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). On the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-rearranged glioma, EGFRvIII and activating rearrangements may confer sensitivity to osimertinib (Abousand et al., 2021; DOI: 10.26502/jcsct.5079114, Cardona et al., 2021; 34498213). However, a case study of a patient with multiple glioblastoma tumors reported that the tumor harboring EGFRvIII and EGFR amplification did not respond to osimertinib (Makhlin et al., 2019; 31769726). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR-altered glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Cardona et al., 2021; 34498213, Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). Osimertinib has been studied primarily for the treatment of EGFR-mutated NSCLC. A Phase 2 study of osimertinib for EGFR-TKI-naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively (Cho et al., 2020; 31825714). The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non-small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early-stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer disease-free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3-2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Gefitinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR-rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Patients with refractory advanced esophageal carcinoma and EGFR amplification derived significant OS benefit from gefitinib compared with placebo (HR=0.21) (Petty et al., 2017; 28537764, Dutton et al., 2014; 24950987). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a clinical study for patients with glioblastoma (GBM) treated with gefitinib or erlotinib, 24% (4/17) of patients treated with gefitinib experienced tumor shrinkage of 44-87%; furthermore, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). Phase 2 studies of gefitinib for patients with high-grade glioma (HGG; including GBM, anaplastic astrocytoma, and oligodendroglioma) (Franceschi et al., 2007; 17353924) or solely GBM (Rich et al., 2004; 14638850) reported disease stabilization for 18% (5/28) and 42% (22/52) of patients, respectively; however, these and other Phase 1/2 studies reported that efficacy did not correlate with EGFR expression (Uhm et al., 2011; 20510539, Kreisl et al., 2009; 19018475, Franceschi et al., 2007; 17353924, Rich et al., 2004; 14638850). Similarly, a Phase 1/2 study of gefitinib plus radiotherapy for 178 patients with GBM reported no OS benefit of added gefitinib, and EGFR expression was found to be of no prognostic value (Chakravarti et al., 2013; 23182702). However, Phase 1 and Phase 2 trials for HGG have reported clinical benefit from combining gefitinib with other modalities, including the mTOR inhibitors sirolimus (n=34; 2 PRs [5.9%], 13 SDs [38%]) (Reardon et al., 2006; 16467100) and everolimus (n=22; 3 PRs [14%], 8 SDs [36%]) (Kreisl et al., 2009; 19018475) and the VEGF inhibitor cediranib (n=19; 8 PRs [42%]) (Brown et al., 2016; 27232884). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Erlotinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Responses to erlotinib have been reported for patients with EGFR rearrangements (Konduri et al., 2016; 27102076, Zhu et al., 2018; 29290255, Wang et al., 2018; 30255937, Baik et al., 2015; 26398831, Xu et al., 2018; ASCO Abstract e13538). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activating mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma (Hainsworth et al., 2018; 29320312). A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months (Nie et al., 2018; 29998897). A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer PFS relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months) (Prados et al., 2009; 19075262). However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity (Kesavabhotla et al., 2012; 22946346). In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in OS compared with historical controls; sorafenib was found to increase erlotinib clearance (Peereboom et al., 2013; 23328813). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04946968">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04670679">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02800486">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02861898">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04547777">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
            <Alteration>
              <Name>amplification</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="amplification" />
              </AlterationProperties>
              <Interpretation>EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). Amplification of EGFR has been associated with increased expression of EGFR mRNA and protein in several cancer types (Liang et al., 2010; 20637128, Bhargava et al., 2005; 15920544, Yang et al., 2012; 22490401). A mutation of the EGFR gene, referred to as EGFRvIII, results from a gene rearrangement that deletes exons 2-7. This alteration causes an in-frame deletion of 801 base pairs encoding part of the extracellular ligand-binding domain (Nishikawa et al., 1994; 8052651). This deletion has shown to result in ligand-independent (constitutive) phosphorylation and activation of EGFR, as well as consequent tumorigenesis (Nishikawa et al., 1994; 8052651, Nedergaard et al., 2012; 22385404). EGFR mutations that have been characterized in biochemical assays to be activating, as observed here, are predicted to confer sensitivity to EGFR-targeted therapies (Foster et al., 2010; 20942962, Cai et al., 2008; 18193092, Stabile et al., 2005; 15735034, Zhang et al., 2006; 17409930, Siegfried et al., 2012; 22258476, ManChon et al., 2014; 24743239, Cho et al., 2014; 24894453, Hama et al., 2009; 19726454, Tam et al., 2009; 19671738, Kancha et al., 2009; 19147750, Chen et al., 2006; 16205628, Lee et al., 2006; 17177598, Ymer et al., 2011; 24212795, Razis et al., 2009; 19789313, Wang et al., 2011; 21532887, Cai et al., 2008; 18193092, Kim et al., 2019; 31290142, Sueangoen et al., 2020; 32190291, Lundby et al., 2019; 31585087). Across several genomic studies of CNS tumors, EGFR amplification has been reported in 16.9% of anaplastic astrocytomas, and 39.7% of glioblastoma multiformes (GBMs)(Jonsson et al., 2019; 31263031, Brennan et al., 2013; 24120142, Ceccarelli et al., 2016; 26824661, Thomas et al., 2017; 28472509). EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors (cbio-Jonsson et al., 2019; 31263031, cbio-Brennan et al., 2013; 24120142, cbio-Ceccarelli et al., 2016; 26824661, cbio-Thomas et al., 2017; 28472509). In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10-15% of cases and approximately half have a low-level amplification of the mutated allele (Lee et al., 2006; 17177598, Vivanco et al., 2012; 22588883). In a study of IDH-wildtype GBM samples, EGFR alterations were detected in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event (Yan et al. 2020; DOI:10.1200/PO.19.00385). The EGFRvIII mutation has been variously reported in 6-46% of GBM samples (Nishikawa et al., 1994; 8052651, Shinojima et al., 2003; 14583498, Nishikawa et al., 2004; 15700833, Mellinghoff et al., 2005; 16282176, Viana-Pereira et al., 2008; 18507036, Yoshimoto et al., 2008; 18223223, Larysz et al., 2011; 21455841, Verhaak et al., 2010; 20129251, Lv et al., 2012; 22752145). No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM (Srividya et al., 2010; 20702468, Das et al., 2011; 20888234); however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM (Smith et al., 2001; 11504770). The link between EGFRvIII status and prognosis is unclear, although some studies suggest that it may be linked to improved survival and response to chemotherapy (Montano et al., 2011; 22241957). In multiple glioblastoma (GBM) studies, the presence of EGFRvIII has not predicted clinical benefit from first-generation EGFR TKIs such as erlotinib (Van den Bent et al., 2009; 19204207, Haas-Kogen et al., 2005; 15956649, Brown et al., 2008; 18955445, Preusser et al., 2008; 18458820, Wen et al., 2014; 24470557, Gallego et al., 2013; 24352766) or gefitinib (Rich et al. 2004; 14638850, Uhm et al., 2011; 20510539, Preusser et al., 2008; 18458820). However, case reports have described patients with EGFRvIII-positive GBM responding to erlotinib (Doyle et al., 2018; 30410775, D'Alessandris et al., 2013; 23132371, Custodio and Perez-Segura, 2010; 20462843, D'Alessandris et al., 2018; 30306271). In a retrospective study of patients with GBM treated with erlotinib or gefitinib, co-expression of EGFRvIII with PTEN protein was the strongest predictor of response (P&lt;0.001)(Mellinghoff et al., 2005; 16282176), suggesting that activity in this setting is dependent on PTEN status (Mellinghoff et al., 2007; 17255257, Arif et al., 2018; 29492119). However, a prospective Phase 2 trial testing erlotinib monotherapy for patients with EGFRvIII and PTEN-positive recurrent glioblastoma reported minimal efficacy and was terminated (Gallego et al., 2013; 24352766). The second-generation EGFR TKIs afatinib and dacomitinib have shown minimal efficacy for patients with EGFRvIII glioblastoma (GBM)(Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602, Sepulveda-Sanchez et al., 2017; 28575464, Chi et al., 2020; 32923886). A Phase 1/2 study of afatinib, temozolomide, or the combination for patients with GBM reported clinical benefit, including for patients with EGFRvIII; however, temozolomide alone and in combination exhibited better responses than afatinib monotherapy (Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602). A Phase 2 trial of dacomitinib for patients with EGFR-amplified GBM reported a DCR of 26% (5/19) among patients with EGFR amplification and EGFRvIII; however, the trial failed to meet its primary endpoint of 6-month PFS (Sepulveda-Sanchez et al., 2017; 28575464). A retrospective biomarker analysis of another Phase 2 study of dacomitinib for patients with GBM found no association between EGFRvIII and clinical benefit (Chi et al., 2020; 32923886). Patients with glioma and co-occurring EGFR amplification and EGFRvIII have reported responses to osimertinib (Cardona et al., 2021; 34498213, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). However, a patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFRvIII, experienced progression of the EGFRvIII-positive tumor during treatment with osimertinib (Makhlin et al., 2019; 31769726). On the basis of preclinical data, osimertinib inhibits EGFRvIIII-driven tumor growth in vitro (Chagoya et al., 2020; 32547705, Gao et al., 2021; 33910930). A single-center Phase 2 pilot study for EGFR-amplified solid tumors (n=13) reported 1 PR and 2 SDs, including 1 with a 9-month duration, for the 8 evaluable patients with glioblastoma (Byeon et al., 2020; 32107712). Novel approaches that specifically target EGFRvIII in glioblastoma (GBM), such as the vaccine rindopepimut, are under investigation in both clinical and preclinical studies. A Phase 2 trial reported significant improvement in OS for patients with EGFRvIII-positive GBM with rindopepimut in combination with bevacizumab compared to bevacizumab alone (HR=0.53, p=0.01)(Reardon et al., 2020; 32034072). However, a Phase 3 study of rindopepimut combined with temozolomide compared to temozolomide alone in newly diagnosed EGFRvIII-positive GBM patients was terminated after the interim analysis, due to a lack of clinical benefit as measured by OS (20 vs. 20 months)(Weller et al., 2017; 28844499). For patients with non-small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR–TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao-Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao-Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with EGFR-mutated bithalamic glioma have reported responses to osimertinib (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses (Mondal et al., 2020; 32303840). On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib (Mondal et al., 2020; 32303840). Clinical studies of the second-generation EGFR TKIs afatinib and dacomitinib for patients with EGFR-amplified gliomas have shown limited efficacy (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886, Reardon et al., 2015; 25140039, Blumenthal et al., 2016; 27531351); however, a small subset of patients has experienced clinical benefit (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886). Multiple studies have failed to find a positive association between increased EGFR expression and clinical benefit from erlotinib or gefitinib for patients with glioblastoma (Mellinghoff et al., 2005; 16282176, Franceschi et al., 2007; 17353924, Chakravarti et al., 2013; 23182702, Hegi et al., 2011; 21471286, Rich et al. 2004; 14638850). There are conflicting data on the efficacy of anti-EGFR antibodies for the treatment of EGFR-amplified tumors. A meta-analysis of colorectal cancer patients treated with second-line or higher cetuximab or panitumumab observed an association between EGFR copy number gain and increased OS and PFS (Jiang et al., 2013; 23441167). However, studies of patients with head and neck squamous cell carcinoma or gastric cancer found either no association or a negative association between EGFR copy number gain and survival after treatment with first-line cetuximab or panitumumab in combination with chemotherapy (Licitra et al., 2011; 21048039, Smyth et al., 2020; 33199443). The Phase 3 INTELLANCE trial of depatuxizumab mafodotin (ABT-414), an EGFR-targeted antibody-drug conjugate with a toxic payload, in patients with EGFR-amplified glioblastoma (GBM) was stopped for futility. Interim analysis demonstrated improved median PFS (mPFS) of ABT-414 monotherapy compared with placebo (HR=0.84); however, no OS benefit was observed (HR=1.01). Improved mPFS was also observed in patients harboring EGFRvIII (HR=0.73) but without an OS improvement (HR=0.95) (Lassman et al., 2019; Neuro-Oncology Abstract ACTR-21). The Phase 2 INTELLANCE trial demonstrated clinical benefit for EGFR-amplified GBM for the combination of ABT-414, temozolomide, and radiotherapy (HR=0.66, p=0.017), but there was no evidence of efficacy for ABT-414 monotherapy (HR=1.04, p=0.83)(Bent et al., 2020; 31747009). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2022) (Louis et al., 2021; 34185076).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cetuximab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 trial of cetuximab with the anti-VEGF monoclonal antibody bevacizumab for patients with glioblastoma (GBM) did not show improved efficacy compared with bevacizumab alone (Hasselbalch et al., 2010; 20406901). However, another Phase 2 study demonstrated that for patients with GBM harboring EGFR amplification but lacking expression of the EGFRvIII variant, treatment with cetuximab resulted in significantly longer PFS and numerical (although not statistically significant) improvement in OS (Lv et al., 2012; 22752145). In addition, a case report for an EGFR-amplified patient with GBM treated with cetuximab using intraarterial cerebral infusion (SIACI) in combination with chemotherapy reported a stable response without recurrence at 6 months (Kulason et al., 2018; 29790314). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Panitumumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1 trial of EnGeneIC delivery vehicle (EDV) targeting EGFR with panitumumab in combination with doxorubicin for 14 patients with glioblastoma (GBM) reported no responses and 28% (4/14) SDs (Whittle et al., 2015; 26279503). Panitumumab has shown efficacy as monotherapy or in combination with chemotherapy for patients with KRAS-wildtype colorectal cancer (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858) and has been investigated in a variety of other tumor types. For patients with head and neck squamous cell carcinoma (HNSCC), data are conflicting; some trials of panitumumab in various lines and with different chemotherapy combinations have shown modest benefit (Vermorken et al., 2013; 23746666, Wirth et al., 2010; 19892746, Siano et al., 2017; 28592616) and others have reported no benefit (Mesia et al., 2015; 25596660, Giralt et al., 2015; 25596659, Siu et al., 2016; 27930762). A Phase 3 study of chemotherapy with or without panitumumab for patients with advanced gastroesophageal cancer was terminated for futility (Waddell et al., 2013; 23594787). Trials in a variety of tumor types have failed to show significant benefit for patients, including non-small cell lung cancer (NSCLC) (Crawford et al., 2013; 24389433, Shuette et al., 2015; 26094080); biliary tract cancers, including cholangiocarcinoma (Leone et al., 2016; 26540314, Vogel et al., 2018; 29413685); and renal cell carcinoma (RCC) (Rowinsky et al., 2004; 15210739). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Osimertinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-mutated glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677) and additional clinical studies suggesting clinical benefit for these patients (Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). On the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-rearranged glioma, EGFRvIII and activating rearrangements may confer sensitivity to osimertinib (Abousand et al., 2021; DOI: 10.26502/jcsct.5079114, Cardona et al., 2021; 34498213). However, a case study of a patient with multiple glioblastoma tumors reported that the tumor harboring EGFRvIII and EGFR amplification did not respond to osimertinib (Makhlin et al., 2019; 31769726). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR-altered glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Cardona et al., 2021; 34498213, Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). Osimertinib has been studied primarily for the treatment of EGFR-mutated NSCLC. A Phase 2 study of osimertinib for EGFR-TKI-naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively (Cho et al., 2020; 31825714). The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non-small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early-stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer disease-free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3-2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Gefitinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR-rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Patients with refractory advanced esophageal carcinoma and EGFR amplification derived significant OS benefit from gefitinib compared with placebo (HR=0.21) (Petty et al., 2017; 28537764, Dutton et al., 2014; 24950987). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a clinical study for patients with glioblastoma (GBM) treated with gefitinib or erlotinib, 24% (4/17) of patients treated with gefitinib experienced tumor shrinkage of 44-87%; furthermore, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). Phase 2 studies of gefitinib for patients with high-grade glioma (HGG; including GBM, anaplastic astrocytoma, and oligodendroglioma) (Franceschi et al., 2007; 17353924) or solely GBM (Rich et al., 2004; 14638850) reported disease stabilization for 18% (5/28) and 42% (22/52) of patients, respectively; however, these and other Phase 1/2 studies reported that efficacy did not correlate with EGFR expression (Uhm et al., 2011; 20510539, Kreisl et al., 2009; 19018475, Franceschi et al., 2007; 17353924, Rich et al., 2004; 14638850). Similarly, a Phase 1/2 study of gefitinib plus radiotherapy for 178 patients with GBM reported no OS benefit of added gefitinib, and EGFR expression was found to be of no prognostic value (Chakravarti et al., 2013; 23182702). However, Phase 1 and Phase 2 trials for HGG have reported clinical benefit from combining gefitinib with other modalities, including the mTOR inhibitors sirolimus (n=34; 2 PRs [5.9%], 13 SDs [38%]) (Reardon et al., 2006; 16467100) and everolimus (n=22; 3 PRs [14%], 8 SDs [36%]) (Kreisl et al., 2009; 19018475) and the VEGF inhibitor cediranib (n=19; 8 PRs [42%]) (Brown et al., 2016; 27232884). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Erlotinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Responses to erlotinib have been reported for patients with EGFR rearrangements (Konduri et al., 2016; 27102076, Zhu et al., 2018; 29290255, Wang et al., 2018; 30255937, Baik et al., 2015; 26398831, Xu et al., 2018; ASCO Abstract e13538). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activating mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma (Hainsworth et al., 2018; 29320312). A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months (Nie et al., 2018; 29998897). A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer PFS relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months) (Prados et al., 2009; 19075262). However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity (Kesavabhotla et al., 2012; 22946346). In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in OS compared with historical controls; sorafenib was found to increase erlotinib clearance (Peereboom et al., 2013; 23328813). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04946968">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04670679">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02800486">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02861898">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04547777">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
            <Alteration>
              <Name>EGFRvIII</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="EGFRvIII" />
              </AlterationProperties>
              <Interpretation>EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide (Ciardiello and Tortora, 2008; 18337605). Amplification of EGFR has been associated with increased expression of EGFR mRNA and protein in several cancer types (Liang et al., 2010; 20637128, Bhargava et al., 2005; 15920544, Yang et al., 2012; 22490401). A mutation of the EGFR gene, referred to as EGFRvIII, results from a gene rearrangement that deletes exons 2-7. This alteration causes an in-frame deletion of 801 base pairs encoding part of the extracellular ligand-binding domain (Nishikawa et al., 1994; 8052651). This deletion has shown to result in ligand-independent (constitutive) phosphorylation and activation of EGFR, as well as consequent tumorigenesis (Nishikawa et al., 1994; 8052651, Nedergaard et al., 2012; 22385404). EGFR mutations that have been characterized in biochemical assays to be activating, as observed here, are predicted to confer sensitivity to EGFR-targeted therapies (Foster et al., 2010; 20942962, Cai et al., 2008; 18193092, Stabile et al., 2005; 15735034, Zhang et al., 2006; 17409930, Siegfried et al., 2012; 22258476, ManChon et al., 2014; 24743239, Cho et al., 2014; 24894453, Hama et al., 2009; 19726454, Tam et al., 2009; 19671738, Kancha et al., 2009; 19147750, Chen et al., 2006; 16205628, Lee et al., 2006; 17177598, Ymer et al., 2011; 24212795, Razis et al., 2009; 19789313, Wang et al., 2011; 21532887, Cai et al., 2008; 18193092, Kim et al., 2019; 31290142, Sueangoen et al., 2020; 32190291, Lundby et al., 2019; 31585087). Across several genomic studies of CNS tumors, EGFR amplification has been reported in 16.9% of anaplastic astrocytomas, and 39.7% of glioblastoma multiformes (GBMs)(Jonsson et al., 2019; 31263031, Brennan et al., 2013; 24120142, Ceccarelli et al., 2016; 26824661, Thomas et al., 2017; 28472509). EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors (cbio-Jonsson et al., 2019; 31263031, cbio-Brennan et al., 2013; 24120142, cbio-Ceccarelli et al., 2016; 26824661, cbio-Thomas et al., 2017; 28472509). In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10-15% of cases and approximately half have a low-level amplification of the mutated allele (Lee et al., 2006; 17177598, Vivanco et al., 2012; 22588883). In a study of IDH-wildtype GBM samples, EGFR alterations were detected in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event (Yan et al. 2020; DOI:10.1200/PO.19.00385). The EGFRvIII mutation has been variously reported in 6-46% of GBM samples (Nishikawa et al., 1994; 8052651, Shinojima et al., 2003; 14583498, Nishikawa et al., 2004; 15700833, Mellinghoff et al., 2005; 16282176, Viana-Pereira et al., 2008; 18507036, Yoshimoto et al., 2008; 18223223, Larysz et al., 2011; 21455841, Verhaak et al., 2010; 20129251, Lv et al., 2012; 22752145). No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM (Srividya et al., 2010; 20702468, Das et al., 2011; 20888234); however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM (Smith et al., 2001; 11504770). The link between EGFRvIII status and prognosis is unclear, although some studies suggest that it may be linked to improved survival and response to chemotherapy (Montano et al., 2011; 22241957). In multiple glioblastoma (GBM) studies, the presence of EGFRvIII has not predicted clinical benefit from first-generation EGFR TKIs such as erlotinib (Van den Bent et al., 2009; 19204207, Haas-Kogen et al., 2005; 15956649, Brown et al., 2008; 18955445, Preusser et al., 2008; 18458820, Wen et al., 2014; 24470557, Gallego et al., 2013; 24352766) or gefitinib (Rich et al. 2004; 14638850, Uhm et al., 2011; 20510539, Preusser et al., 2008; 18458820). However, case reports have described patients with EGFRvIII-positive GBM responding to erlotinib (Doyle et al., 2018; 30410775, D'Alessandris et al., 2013; 23132371, Custodio and Perez-Segura, 2010; 20462843, D'Alessandris et al., 2018; 30306271). In a retrospective study of patients with GBM treated with erlotinib or gefitinib, co-expression of EGFRvIII with PTEN protein was the strongest predictor of response (P&lt;0.001)(Mellinghoff et al., 2005; 16282176), suggesting that activity in this setting is dependent on PTEN status (Mellinghoff et al., 2007; 17255257, Arif et al., 2018; 29492119). However, a prospective Phase 2 trial testing erlotinib monotherapy for patients with EGFRvIII and PTEN-positive recurrent glioblastoma reported minimal efficacy and was terminated (Gallego et al., 2013; 24352766). The second-generation EGFR TKIs afatinib and dacomitinib have shown minimal efficacy for patients with EGFRvIII glioblastoma (GBM)(Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602, Sepulveda-Sanchez et al., 2017; 28575464, Chi et al., 2020; 32923886). A Phase 1/2 study of afatinib, temozolomide, or the combination for patients with GBM reported clinical benefit, including for patients with EGFRvIII; however, temozolomide alone and in combination exhibited better responses than afatinib monotherapy (Reardon et al., 2015; 25140039, Alshami et al., 2015; 26423602). A Phase 2 trial of dacomitinib for patients with EGFR-amplified GBM reported a DCR of 26% (5/19) among patients with EGFR amplification and EGFRvIII; however, the trial failed to meet its primary endpoint of 6-month PFS (Sepulveda-Sanchez et al., 2017; 28575464). A retrospective biomarker analysis of another Phase 2 study of dacomitinib for patients with GBM found no association between EGFRvIII and clinical benefit (Chi et al., 2020; 32923886). Patients with glioma and co-occurring EGFR amplification and EGFRvIII have reported responses to osimertinib (Cardona et al., 2021; 34498213, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). However, a patient with multiple glioblastoma (GBM) tumors, one of which harbored EGFRvIII, experienced progression of the EGFRvIII-positive tumor during treatment with osimertinib (Makhlin et al., 2019; 31769726). On the basis of preclinical data, osimertinib inhibits EGFRvIIII-driven tumor growth in vitro (Chagoya et al., 2020; 32547705, Gao et al., 2021; 33910930). A single-center Phase 2 pilot study for EGFR-amplified solid tumors (n=13) reported 1 PR and 2 SDs, including 1 with a 9-month duration, for the 8 evaluable patients with glioblastoma (Byeon et al., 2020; 32107712). Novel approaches that specifically target EGFRvIII in glioblastoma (GBM), such as the vaccine rindopepimut, are under investigation in both clinical and preclinical studies. A Phase 2 trial reported significant improvement in OS for patients with EGFRvIII-positive GBM with rindopepimut in combination with bevacizumab compared to bevacizumab alone (HR=0.53, p=0.01)(Reardon et al., 2020; 32034072). However, a Phase 3 study of rindopepimut combined with temozolomide compared to temozolomide alone in newly diagnosed EGFRvIII-positive GBM patients was terminated after the interim analysis, due to a lack of clinical benefit as measured by OS (20 vs. 20 months)(Weller et al., 2017; 28844499). For patients with non-small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR–TKIs, including erlotinib (Rosell et al., 2011; 22285168), gefitinib (Douillard et al., 2014; 24263064, Hayashi et al., 2020; 32673682, Cao et al., 2018; 29780256, Yang et al., 2011; 21422421), afatinib (Sequist et al., 2013; 23816960, Bao-Dong Qin et al., 2018; 30127622, Frega et al., 2016; 27131295, Long et al., 2020; 33116645), dacomitinib (Mok et al., 2018; 29864379), and osimertinib (Janne et al., 2015; 25923549, Bao-Dong Qin et al., 2018; 30127622); however, the data for patients with other tumor types are limited (Hong et al., 2020; 32749686, Kim et al., 2015; 26462025, Kim et al., 2015; 25424851, Mondal et al., 2020; 32303840, Cavalieri et al., 2018; 29734047, Chi et al., 2020; 32923886, Audet et al., 2013; ASCO Abstract 6041). Patients with EGFR-mutated bithalamic glioma have reported responses to osimertinib (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses (Mondal et al., 2020; 32303840). On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib (Mondal et al., 2020; 32303840). Clinical studies of the second-generation EGFR TKIs afatinib and dacomitinib for patients with EGFR-amplified gliomas have shown limited efficacy (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886, Reardon et al., 2015; 25140039, Blumenthal et al., 2016; 27531351); however, a small subset of patients has experienced clinical benefit (Sepulveda-Sanchez et al., 2017; 28575464, Tanaka et al., 2019; 30644426, Chi et al., 2020; 32923886). Multiple studies have failed to find a positive association between increased EGFR expression and clinical benefit from erlotinib or gefitinib for patients with glioblastoma (Mellinghoff et al., 2005; 16282176, Franceschi et al., 2007; 17353924, Chakravarti et al., 2013; 23182702, Hegi et al., 2011; 21471286, Rich et al. 2004; 14638850). There are conflicting data on the efficacy of anti-EGFR antibodies for the treatment of EGFR-amplified tumors. A meta-analysis of colorectal cancer patients treated with second-line or higher cetuximab or panitumumab observed an association between EGFR copy number gain and increased OS and PFS (Jiang et al., 2013; 23441167). However, studies of patients with head and neck squamous cell carcinoma or gastric cancer found either no association or a negative association between EGFR copy number gain and survival after treatment with first-line cetuximab or panitumumab in combination with chemotherapy (Licitra et al., 2011; 21048039, Smyth et al., 2020; 33199443). The Phase 3 INTELLANCE trial of depatuxizumab mafodotin (ABT-414), an EGFR-targeted antibody-drug conjugate with a toxic payload, in patients with EGFR-amplified glioblastoma (GBM) was stopped for futility. Interim analysis demonstrated improved median PFS (mPFS) of ABT-414 monotherapy compared with placebo (HR=0.84); however, no OS benefit was observed (HR=1.01). Improved mPFS was also observed in patients harboring EGFRvIII (HR=0.73) but without an OS improvement (HR=0.95) (Lassman et al., 2019; Neuro-Oncology Abstract ACTR-21). The Phase 2 INTELLANCE trial demonstrated clinical benefit for EGFR-amplified GBM for the combination of ABT-414, temozolomide, and radiotherapy (HR=0.66, p=0.017), but there was no evidence of efficacy for ABT-414 monotherapy (HR=1.04, p=0.83)(Bent et al., 2020; 31747009). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2022) (Louis et al., 2021; 34185076).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</ClinicalTrialNote>
              <Therapies>
                <Therapy>
                  <Name />
                  <GenericName>Cetuximab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 2 trial of cetuximab with the anti-VEGF monoclonal antibody bevacizumab for patients with glioblastoma (GBM) did not show improved efficacy compared with bevacizumab alone (Hasselbalch et al., 2010; 20406901). However, another Phase 2 study demonstrated that for patients with GBM harboring EGFR amplification but lacking expression of the EGFRvIII variant, treatment with cetuximab resulted in significantly longer PFS and numerical (although not statistically significant) improvement in OS (Lv et al., 2012; 22752145). In addition, a case report for an EGFR-amplified patient with GBM treated with cetuximab using intraarterial cerebral infusion (SIACI) in combination with chemotherapy reported a stable response without recurrence at 6 months (Kulason et al., 2018; 29790314). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Panitumumab</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; For patients with metastatic CRC receiving cetuximab or panitumumab as mono- or combination therapy, increased EGFR copy number associated with improved OS (HR=0.62) in a meta-analysis, although increased survival was not seen in populations that received first-line treatment with EGFR antibodies (Jiang et al., 2013; 23441167). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; A Phase 1 trial of EnGeneIC delivery vehicle (EDV) targeting EGFR with panitumumab in combination with doxorubicin for 14 patients with glioblastoma (GBM) reported no responses and 28% (4/14) SDs (Whittle et al., 2015; 26279503). Panitumumab has shown efficacy as monotherapy or in combination with chemotherapy for patients with KRAS-wildtype colorectal cancer (Douillard et al., 2014; 24718886, Price et al., 2014; 24739896, Van Cutsem et al., 2007; 17470858) and has been investigated in a variety of other tumor types. For patients with head and neck squamous cell carcinoma (HNSCC), data are conflicting; some trials of panitumumab in various lines and with different chemotherapy combinations have shown modest benefit (Vermorken et al., 2013; 23746666, Wirth et al., 2010; 19892746, Siano et al., 2017; 28592616) and others have reported no benefit (Mesia et al., 2015; 25596660, Giralt et al., 2015; 25596659, Siu et al., 2016; 27930762). A Phase 3 study of chemotherapy with or without panitumumab for patients with advanced gastroesophageal cancer was terminated for futility (Waddell et al., 2013; 23594787). Trials in a variety of tumor types have failed to show significant benefit for patients, including non-small cell lung cancer (NSCLC) (Crawford et al., 2013; 24389433, Shuette et al., 2015; 26094080); biliary tract cancers, including cholangiocarcinoma (Leone et al., 2016; 26540314, Vogel et al., 2018; 29413685); and renal cell carcinoma (RCC) (Rowinsky et al., 2004; 15210739). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Osimertinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer (Janne et al., 2015; 25923549, Soria et al., 2018; 29151359, Alanazi et al., 2020; 33318755, Kim et al., 2021; DOI: 10.1200/PO.20.00296, Wang et al., 2018; 30255937). EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-mutated glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677) and additional clinical studies suggesting clinical benefit for these patients (Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). On the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-rearranged glioma, EGFRvIII and activating rearrangements may confer sensitivity to osimertinib (Abousand et al., 2021; DOI: 10.26502/jcsct.5079114, Cardona et al., 2021; 34498213). However, a case study of a patient with multiple glioblastoma tumors reported that the tumor harboring EGFRvIII and EGFR amplification did not respond to osimertinib (Makhlin et al., 2019; 31769726). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR-altered glioma (Makhlin et al., 2019; 31769726, Goyal et al., 2021; 33940677, Cardona et al., 2021; 34498213, Mondal et al., 2020; 32303840, Abousand et al., 2021; DOI: 10.26502/jcsct.5079114). Osimertinib has been studied primarily for the treatment of EGFR-mutated NSCLC. A Phase 2 study of osimertinib for EGFR-TKI-naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively (Cho et al., 2020; 31825714). The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non-small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858) (Soria et al., 2018; 29151359, Ramalingam et al., 2019; 31751012). In the Phase 3 ADAURA study, patients with early-stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer disease-free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27) (Tsuboi et al., 2022; ESMO Abstract LBA47). A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months (Janne et al., 2015; 25923549). A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213) (Kenmotsu et al., 2022; 35636696). The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47) (Soo et al., 2021; ESMO Abstract VP3-2021). The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively (Oxnard et al., 2020; 32139298). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Gefitinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy (Han et al., 2012; 22370314, Maemondo et al., 2010; 20573926, Mitsudomi et al., 2010; 20022809, Mok et al., 2009; 19692680, Petrelli et al., 2011; 22056888, Qi et al., 2015; 25329826, Zhao et al., 2015; 25546556), and responses have been reported for patients with EGFR-rearranged NSCLC (Wang et al., 2018; 30255937, Baik et al., 2015; 26398831). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Patients with refractory advanced esophageal carcinoma and EGFR amplification derived significant OS benefit from gefitinib compared with placebo (HR=0.21) (Petty et al., 2017; 28537764, Dutton et al., 2014; 24950987). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In a clinical study for patients with glioblastoma (GBM) treated with gefitinib or erlotinib, 24% (4/17) of patients treated with gefitinib experienced tumor shrinkage of 44-87%; furthermore, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). Phase 2 studies of gefitinib for patients with high-grade glioma (HGG; including GBM, anaplastic astrocytoma, and oligodendroglioma) (Franceschi et al., 2007; 17353924) or solely GBM (Rich et al., 2004; 14638850) reported disease stabilization for 18% (5/28) and 42% (22/52) of patients, respectively; however, these and other Phase 1/2 studies reported that efficacy did not correlate with EGFR expression (Uhm et al., 2011; 20510539, Kreisl et al., 2009; 19018475, Franceschi et al., 2007; 17353924, Rich et al., 2004; 14638850). Similarly, a Phase 1/2 study of gefitinib plus radiotherapy for 178 patients with GBM reported no OS benefit of added gefitinib, and EGFR expression was found to be of no prognostic value (Chakravarti et al., 2013; 23182702). However, Phase 1 and Phase 2 trials for HGG have reported clinical benefit from combining gefitinib with other modalities, including the mTOR inhibitors sirolimus (n=34; 2 PRs [5.9%], 13 SDs [38%]) (Reardon et al., 2006; 16467100) and everolimus (n=22; 3 PRs [14%], 8 SDs [36%]) (Kreisl et al., 2009; 19018475) and the VEGF inhibitor cediranib (n=19; 8 PRs [42%]) (Brown et al., 2016; 27232884). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
                <Therapy>
                  <Name />
                  <GenericName>Erlotinib</GenericName>
                  <FDAApproved>false</FDAApproved>
                  <Rationale>&lt;p&gt;&lt;b&gt;Approved Indications:&lt;/b&gt; Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Gene Association:&lt;/b&gt; Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression (Cappuzzo et al., 2010; 20493771, Rosell et al., 2012; 22285168, Zhong et al., 2019; 31194613, Petrelli et al., 2011; 22056888). For patients with esophageal or biliary cancer treated with erlotinib or gefitinib, elevated EGFR copy number or amplification is associated with clinical responses and longer survival (Petty et al., 2017; 28537764, Philip et al., 2006; 16809731, Xie et al., 2020; 32958820, Luo et al., 2020; 33026449, Lee et al., 2012; 22192731). Responses to erlotinib have been reported for patients with EGFR rearrangements (Konduri et al., 2016; 27102076, Zhu et al., 2018; 29290255, Wang et al., 2018; 30255937, Baik et al., 2015; 26398831, Xu et al., 2018; ASCO Abstract e13538). &lt;/p&gt; &lt;p&gt;&lt;b&gt;Supporting Data:&lt;/b&gt; In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activating mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma (Hainsworth et al., 2018; 29320312). A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months (Nie et al., 2018; 29998897). A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response (Mellinghoff et al., 2005; 16282176). In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer PFS relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months) (Prados et al., 2009; 19075262). However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity (Kesavabhotla et al., 2012; 22946346). In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in OS compared with historical controls; sorafenib was found to increase erlotinib clearance (Peereboom et al., 2013; 23328813). &lt;/p&gt;</Rationale>
                  <ApprovedUses />
                  <Effect>Sensitizing</Effect>
                  <Include>true</Include>
                  <IncludeInSummary>true</IncludeInSummary>
                  <ReferenceLinks />
                </Therapy>
              </Therapies>
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT03239015">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04946968">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04720976">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04670679">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02800486">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02861898">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04547777">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>MTAP</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>loss</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="loss" />
              </AlterationProperties>
              <Interpretation>MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity (Limm et al., 2016; 27479139, Tang et al., 2014; 25387827). Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment (Kirovski et al., 2011; 21356366, Limm et al., 2013; 23265702, Stevens et al., 2009; 19097084), thereby reducing intracellular arginine methylation (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360) and altering cell signaling (Limm et al., 2014; 25087184, Stevens et al., 2009; 19097084). MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized. MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers (Wei et al., 2016; 27929028, Zhao and Zhao, 2016; 27556634); such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma (Kirovski et al., 2011; 21356366), gastrointestinal stromal tumors (Huang et al., 2009; 19887491), mantle cell lymphoma (MCL)(Marce et al., 2006; 16778103), melanoma (Meyer et al., 2010; 20500769, Wild et al., 2006; 16618867), gastric cancer (Kim et al., 2011; 21412930), myxofibrosarcoma (Li et al., 2014; 25426549), nasopharyngeal carcinoma (He et al., 2015; 26656376), ovarian carcinoma (Wei et al., 2016; 27929028) and non-small cell lung cancer (Su et al., 2014; 24969958). MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia (Mirebeau et al., 2006; 16818274) or in astrocytoma (Becker et al., 2015; 26088413). However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples (Snezhkina et al., 2016; 27433286), and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM (Bistulfi et al., 2016; 26910893). Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma (Antonopoulou et al., 2015; 25407435, Mccioni et al., 2013; 23816148), esophageal cancer (Hyland et al., 2016; 26635288, Lin et al., 2017; 27960044), osteosarcoma (Zhi et al., 2016; 27994653), and CRC (Gu et al., 2013; 23361049). MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A (Kalev et al., 2021; 33450196, Heist et al., 2019; AACR-NCI-EORTC Abstract B116, Marjon et al., 2016; 27068473) or PRMT5 inhibition (Marjon et al., 2016; 27068473, Mavrakis et al., 2016; 26912361, Kryukov et al., 2016; 26912360). A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss (Heist et al., 2019; AACR-NCI-EORTC Abstract B116). Preclinical data suggest that MTAP loss sensitizes cells to S-adenosyl-L-methionine (SAM)-competitive PRMT5 inhibitors (Guccione and Richard, 2019; 31350521), dual PRMT1 and PRMT5 inhibitors (Fedoriw et al., 2019; 31257072, Srour et al., 2019; 31287990, Gao et al., 2019; 30916320), and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S-methyl-5'-thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193 (Smith et al., 2022; 35041419, Briggs et al., 2022; AACR Abstract 3941). In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA (Hansen et al., 2019; 31040154, Tang et al., 2018; 29844120, Munshi et al., 2014; 24928612, de Oliveira et al., 2016; 26751376, Lubin and Lubin, 2009; 19478948, Tang et al., 2012; 22825330, Collins et al., 2012; 22252602, Bertino et al., 2011; 21301207, Coulthard et al., 2011; 21282358, Miyazaki et al., 2007; 17912432, Efferth et al., 2002; 11987241). A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and SD for 24% (13/55) of patients (Kindler et al., 2009; 18618081). Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed (Alhalabi et al., 2022; 35379845).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT05245500">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>PTEN</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>splice site 634+1G&gt;A</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="59.56" isEquivocal="false" name="splice site 634+1G&gt;A" />
              </AlterationProperties>
              <Interpretation>PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodríguez-Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andrés-Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio-Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Decreased PTEN expression is associated with the higher grade GBM tumors (Sano et al., 1999; 10213484). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus (Galanis et al., 2005; 15998902, Kreisl et al., 2009; 19018475, Mason et al., 2011; 22160854). Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes-Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha-Paul et al., 2018; AACR Abstract A096). One or more of the PTEN variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary cancer-predisposing syndrome (ClinVar, Apr 2023)(Landrum et al., 2018; 29165669). Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</ClinicalTrialNote>
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks>
                <ClinicalTrialLink nctId="NCT02264678">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04740190">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05021367">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05035745">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT03772561">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04614909">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05076513">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT05327010">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT04317105">
                  <Include>true</Include>
                </ClinicalTrialLink>
                <ClinicalTrialLink nctId="NCT02769962">
                  <Include>true</Include>
                </ClinicalTrialLink>
              </ClinicalTrialLinks>
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>CDKN2A/B</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>CDKN2A loss</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="CDKN2A loss" />
              </AlterationProperties>
              <Interpretation>CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio-Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio-Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in glioblastoma (GBM) and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared with patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter OS in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
            <Alteration>
              <Name>CDKN2B loss</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="CDKN2B loss" />
              </AlterationProperties>
              <Interpretation>CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). CDKN2B alterations such as seen here are predicted to inactivate p15INK4b (Jafri et al., 2015; 25873077). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio-Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio-Brennan et al., 2013; 24120142) than in those with lower grade gliomas (6%) (Jonsson et al., 2019; 31263031). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF-encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH-wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in glioblastoma (GBM) and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared with patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter OS in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib (Fennell et al., 2022; 35157829) and palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889). However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib (Infante et al., 2014; ASCO Abstract 2528, Shapiro et al., 2013; ASCO Abstract 2500, Flaherty et al., 2012; 22090362, Dickson et al., 2013; 23569312, Finn et al., 2015; 25524798, DeMichele et al., 2014; 25501126), direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited (Su et al., 2019; 31700061, Tramontana et al., 2020; 32923894). Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Microsatellite status</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>MS-Stable</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="MS-Stable" />
              </AlterationProperties>
              <Interpretation>Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO-SITC Abstract P60).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>TERT</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>promoter -146C&gt;T</Name>
              <AlterationProperties>
                <AlterationProperty dnaFraction="38.41" isEquivocal="false" name="promoter -146C&gt;T" />
              </AlterationProperties>
              <Interpretation>Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions –124/–125 bp and –138/–139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51-59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%) (Nonoguchi et al., 2013; 23955565, Killela et al., 2013; 23530248). One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v2.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v2.2022)(Weller et al., 2020; 33293629). The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v2.2022) (Louis et al., 2021; 34185076).</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
        <Gene>
          <Name>Tumor Mutation Burden</Name>
          <Include>true</Include>
          <Alterations>
            <Alteration>
              <Name>02</Name>
              <AlterationProperties>
                <AlterationProperty isEquivocal="false" name="02" />
              </AlterationProperties>
              <Interpretation>Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide-based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya-Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (&gt;20 muts/Mb)(FMI-Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti-PD-1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya-Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti-PD-L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.</Interpretation>
              <Include>true</Include>
              <ClinicalTrialNote />
              <Therapies />
              <ReferenceLinks />
              <ClinicalTrialLinks />
            </Alteration>
          </Alterations>
          <ReferenceLinks />
        </Gene>
      </Genes>
      <Trials>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6</Target>
          <Locations>Shanghai (China)</Locations>
          <NCTID>NCT03239015</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>ERBB4, EGFR, ERBB2</Target>
          <Locations>Singapore (Singapore)</Locations>
          <NCTID>NCT04946968</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>JAB-3312 Activity in Adult Patients With Advanced Solid Tumors</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>MEK, SHP2, PD-1, EGFR, KRAS</Target>
          <Locations>Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut</Locations>
          <NCTID>NCT04720976</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>SHP2, EGFR</Target>
          <Locations>Perth (Australia), Melbourne (Australia), Nevada, California, Missouri, Texas, Massachusetts, New York, Pennsylvania, Tennessee</Locations>
          <NCTID>NCT04670679</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>EGFR</Target>
          <Locations>New York</Locations>
          <NCTID>NCT02800486</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>EGFR</Target>
          <Locations>New York</Locations>
          <NCTID>NCT02861898</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>EGFR</Gene>
          <Alteration>G598VamplificationEGFRvIII</Alteration>
          <Title>Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>EGFRvIII, CD40</Target>
          <Locations>North Carolina</Locations>
          <NCTID>NCT04547777</NCTID>
          <Note>EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>MTAP</Gene>
          <Alteration>loss</Alteration>
          <Title>Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PRMT5-MTA</Target>
          <Locations>Colorado, Arizona, Minnesota, Massachusetts, New York, Tennessee, Texas, Florida</Locations>
          <NCTID>NCT05245500</NCTID>
          <Note>MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>ATR, PARP, PD-L1</Target>
          <Locations>Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)</Locations>
          <NCTID>NCT02264678</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP</Target>
          <Locations>Hong Kong (Hong Kong)</Locations>
          <NCTID>NCT04740190</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PARP</Target>
          <Locations>Guangzhou (China)</Locations>
          <NCTID>NCT05021367</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Selinexor &amp; Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>XPO1, PARP</Target>
          <Locations>Singapore (Singapore)</Locations>
          <NCTID>NCT05035745</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies</Title>
          <StudyPhase>PHASE 1</StudyPhase>
          <Target>PARP, AKTs, PD-L1</Target>
          <Locations>Singapore (Singapore)</Locations>
          <NCTID>NCT03772561</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>PARP</Target>
          <Locations>Arizona</Locations>
          <NCTID>NCT04614909</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma</Title>
          <StudyPhase>PHASE null</StudyPhase>
          <Target>PARP</Target>
          <Locations>Arizona</Locations>
          <NCTID>NCT05076513</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial</Title>
          <StudyPhase>PHASE 2</StudyPhase>
          <Target>PARP, BRD4, BRDT, BRD2, BRD3</Target>
          <Locations>Colorado, Illinois, Texas, North Carolina, Georgia</Locations>
          <NCTID>NCT05327010</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PD-1, CTLA-4, PI3K</Target>
          <Locations>Toronto (Canada), Texas, Virginia</Locations>
          <NCTID>NCT04317105</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
        <Trial>
          <Gene>PTEN</Gene>
          <Alteration>splice site 634+1G&gt;A</Alteration>
          <Title>Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer</Title>
          <StudyPhase>PHASE 1/2</StudyPhase>
          <Target>PARP, TOP1</Target>
          <Locations>Maryland</Locations>
          <NCTID>NCT02769962</NCTID>
          <Note>PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.</Note>
          <Include>true</Include>
        </Trial>
      </Trials>
      <References>
        <Reference number="0">
          <ReferenceId>27479139</ReferenceId>
          <FullCitation>Limm K, et al. PLoS ONE (2016) pmid: 27479139</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="1">
          <ReferenceId>25387827</ReferenceId>
          <FullCitation>Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="2">
          <ReferenceId>21356366</ReferenceId>
          <FullCitation>Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="3">
          <ReferenceId>23265702</ReferenceId>
          <FullCitation>Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="4">
          <ReferenceId>19097084</ReferenceId>
          <FullCitation>Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="5">
          <ReferenceId>27068473</ReferenceId>
          <FullCitation>Marjon K, et al. Cell Rep (2016) pmid: 27068473</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="6">
          <ReferenceId>26912361</ReferenceId>
          <FullCitation>Mavrakis KJ, et al. Science (2016) pmid: 26912361</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="7">
          <ReferenceId>26912360</ReferenceId>
          <FullCitation>Kryukov GV, et al. Science (2016) pmid: 26912360</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="8">
          <ReferenceId>25087184</ReferenceId>
          <FullCitation>Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="9">
          <ReferenceId>27929028</ReferenceId>
          <FullCitation>Wei R, et al. Sci Rep (2016) pmid: 27929028</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="10">
          <ReferenceId>27556634</ReferenceId>
          <FullCitation>Zhao M, et al. BMC Genomics (2016) pmid: 27556634</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="11">
          <ReferenceId>19887491</ReferenceId>
          <FullCitation>Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="12">
          <ReferenceId>16778103</ReferenceId>
          <FullCitation>Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="13">
          <ReferenceId>20500769</ReferenceId>
          <FullCitation>Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="14">
          <ReferenceId>16618867</ReferenceId>
          <FullCitation>Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="15">
          <ReferenceId>21412930</ReferenceId>
          <FullCitation>Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="16">
          <ReferenceId>25426549</ReferenceId>
          <FullCitation>Li CF, et al. Oncotarget (2014) pmid: 25426549</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="17">
          <ReferenceId>26656376</ReferenceId>
          <FullCitation>He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="18">
          <ReferenceId>24969958</ReferenceId>
          <FullCitation>Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="19">
          <ReferenceId>16818274</ReferenceId>
          <FullCitation>Mirebeau D, et al. Haematologica (2006) pmid: 16818274</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="20">
          <ReferenceId>26088413</ReferenceId>
          <FullCitation>Becker AP, et al. Pathobiology (2015) pmid: 26088413</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="21">
          <ReferenceId>27433286</ReferenceId>
          <FullCitation>Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="22">
          <ReferenceId>26910893</ReferenceId>
          <FullCitation>Bistulfi G, et al. Oncotarget (2016) pmid: 26910893</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="23">
          <ReferenceId>25407435</ReferenceId>
          <FullCitation>Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="24">
          <ReferenceId>23816148</ReferenceId>
          <FullCitation>Maccioni L, et al. BMC Cancer (2013) pmid: 23816148</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="25">
          <ReferenceId>26635288</ReferenceId>
          <FullCitation>Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="26">
          <ReferenceId>27960044</ReferenceId>
          <FullCitation>Lin X, et al. Cancer Sci. (2017) pmid: 27960044</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="27">
          <ReferenceId>27994653</ReferenceId>
          <FullCitation>Zhi L, et al. J Cancer (2016) pmid: 27994653</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="28">
          <ReferenceId>23361049</ReferenceId>
          <FullCitation>Gu F, et al. Br. J. Cancer (2013) pmid: 23361049</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="29">
          <ReferenceId>33450196</ReferenceId>
          <FullCitation>Kalev P, et al. Cancer Cell (2021) pmid: 33450196</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="30">
          <ReferenceId>31350521</ReferenceId>
          <FullCitation>Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="31">
          <ReferenceId>31257072</ReferenceId>
          <FullCitation>Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="32">
          <ReferenceId>31287990</ReferenceId>
          <FullCitation>Srour N, et al. Cancer Cell (2019) pmid: 31287990</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="33">
          <ReferenceId>30916320</ReferenceId>
          <FullCitation>Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="34">
          <ReferenceId>35041419</ReferenceId>
          <FullCitation>Smith CR, et al. J Med Chem (2022) pmid: 35041419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="35">
          <ReferenceId>31040154</ReferenceId>
          <FullCitation>Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="36">
          <ReferenceId>29844120</ReferenceId>
          <FullCitation>Tang B, et al. Cancer Res. (2018) pmid: 29844120</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="37">
          <ReferenceId>24928612</ReferenceId>
          <FullCitation>Munshi PN, et al. Oncologist (2014) pmid: 24928612</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="38">
          <ReferenceId>26751376</ReferenceId>
          <FullCitation>de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="39">
          <ReferenceId>19478948</ReferenceId>
          <FullCitation>Lubin M, et al. PLoS ONE (2009) pmid: 19478948</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="40">
          <ReferenceId>22825330</ReferenceId>
          <FullCitation>Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="41">
          <ReferenceId>22252602</ReferenceId>
          <FullCitation>Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="42">
          <ReferenceId>21301207</ReferenceId>
          <FullCitation>Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="43">
          <ReferenceId>21282358</ReferenceId>
          <FullCitation>Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="44">
          <ReferenceId>17912432</ReferenceId>
          <FullCitation>Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="45">
          <ReferenceId>11987241</ReferenceId>
          <FullCitation>Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="46">
          <ReferenceId>18618081</ReferenceId>
          <FullCitation>Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="47">
          <ReferenceId>35379845</ReferenceId>
          <FullCitation>Alhalabi O, et al. Nat Commun (2022) pmid: 35379845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="48">
          <ReferenceId>11237521</ReferenceId>
          <FullCitation>Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="49">
          <ReferenceId>12857747</ReferenceId>
          <FullCitation>Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="50">
          <ReferenceId>21828076</ReferenceId>
          <FullCitation>Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="51">
          <ReferenceId>23475934</ReferenceId>
          <FullCitation>He X, et al. Cancer Res. (2013) pmid: 23475934</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="52">
          <ReferenceId>10866302</ReferenceId>
          <FullCitation>Han SY, et al. Cancer Res. (2000) pmid: 10866302</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="53">
          <ReferenceId>9811831</ReferenceId>
          <FullCitation>Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="54">
          <ReferenceId>24498881</ReferenceId>
          <FullCitation>Pradella LM, et al. BMC Cancer (2014) pmid: 24498881</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="55">
          <ReferenceId>21536651</ReferenceId>
          <FullCitation>Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="56">
          <ReferenceId>17213812</ReferenceId>
          <FullCitation>Denning G, et al. Oncogene (2007) pmid: 17213812</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="57">
          <ReferenceId>16619501</ReferenceId>
          <FullCitation>Hlobilkova A, et al. Anticancer Res. () pmid: 16619501</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="58">
          <ReferenceId>20718038</ReferenceId>
          <FullCitation>Redfern RE, et al. Protein Sci. (2010) pmid: 20718038</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="59">
          <ReferenceId>22505997</ReferenceId>
          <FullCitation>Shenoy S, et al. PLoS ONE (2012) pmid: 22505997</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="60">
          <ReferenceId>19329485</ReferenceId>
          <FullCitation>Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="61">
          <ReferenceId>16829519</ReferenceId>
          <FullCitation>Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="62">
          <ReferenceId>10555148</ReferenceId>
          <FullCitation>Lee JO, et al. Cell (1999) pmid: 10555148</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="63">
          <ReferenceId>9635567</ReferenceId>
          <FullCitation>Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="64">
          <ReferenceId>9865913</ReferenceId>
          <FullCitation>Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="65">
          <ReferenceId>11051241</ReferenceId>
          <FullCitation>Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="66">
          <ReferenceId>22891331</ReferenceId>
          <FullCitation>Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="67">
          <ReferenceId>23066114</ReferenceId>
          <FullCitation>Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="68">
          <ReferenceId>19457929</ReferenceId>
          <FullCitation>Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="69">
          <ReferenceId>23995781</ReferenceId>
          <FullCitation>Liu J, et al. Oncogene (2014) pmid: 23995781</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="70">
          <ReferenceId>11395408</ReferenceId>
          <FullCitation>Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="71">
          <ReferenceId>10807691</ReferenceId>
          <FullCitation>De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="72">
          <ReferenceId>10051603</ReferenceId>
          <FullCitation>Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="73">
          <ReferenceId>15988030</ReferenceId>
          <FullCitation>Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="74">
          <ReferenceId>15026806</ReferenceId>
          <FullCitation>Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="75">
          <ReferenceId>25875300</ReferenceId>
          <FullCitation>Gil A, et al. PLoS ONE (2015) pmid: 25875300</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="76">
          <ReferenceId>9823298</ReferenceId>
          <FullCitation>Furnari FB, et al. Cancer Res. (1998) pmid: 9823298</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="77">
          <ReferenceId>25527629</ReferenceId>
          <FullCitation>Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="78">
          <ReferenceId>29706633</ReferenceId>
          <FullCitation>Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="79">
          <ReferenceId>20538496</ReferenceId>
          <FullCitation>Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="80">
          <ReferenceId>17942903</ReferenceId>
          <FullCitation>Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="81">
          <ReferenceId>15805158</ReferenceId>
          <FullCitation>Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="82">
          <ReferenceId>10468583</ReferenceId>
          <FullCitation>Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="83">
          <ReferenceId>12085208</ReferenceId>
          <FullCitation>Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="84">
          <ReferenceId>24292679</ReferenceId>
          <FullCitation>Nguyen HN, et al. Oncogene (2014) pmid: 24292679</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="85">
          <ReferenceId>19114656</ReferenceId>
          <FullCitation>Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="86">
          <ReferenceId>12808147</ReferenceId>
          <FullCitation>Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="87">
          <ReferenceId>18498243</ReferenceId>
          <FullCitation>Wang X, et al. Biochem. J. (2008) pmid: 18498243</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="88">
          <ReferenceId>15951562</ReferenceId>
          <FullCitation>Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="89">
          <ReferenceId>25263454</ReferenceId>
          <FullCitation>Nguyen HN, et al. Oncogene (2015) pmid: 25263454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="90">
          <ReferenceId>32704382</ReferenceId>
          <FullCitation>Shan L, et al. Cell Discov (2020) pmid: 32704382</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="91">
          <ReferenceId>10096247</ReferenceId>
          <FullCitation>Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="92">
          <ReferenceId>9331072</ReferenceId>
          <FullCitation>Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="93">
          <ReferenceId>10188904</ReferenceId>
          <FullCitation>Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="94">
          <ReferenceId>11504770</ReferenceId>
          <FullCitation>Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="95">
          <ReferenceId>9796977</ReferenceId>
          <FullCitation>Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="96">
          <ReferenceId>10560660</ReferenceId>
          <FullCitation>Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="97">
          <ReferenceId>17974913</ReferenceId>
          <FullCitation>Furnari FB, et al. Genes Dev. (2007) pmid: 17974913</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="98">
          <ReferenceId>24120142</ReferenceId>
          <FullCitation>Brennan CW, et al. Cell (2013) pmid: 24120142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="99">
          <ReferenceId>26061751</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="100">
          <ReferenceId>10213484</ReferenceId>
          <FullCitation>Sano T, et al. Cancer Res. (1999) pmid: 10213484</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="101">
          <ReferenceId>21134002</ReferenceId>
          <FullCitation>Srividya MR, et al. Neuropathology (2011) pmid: 21134002</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="102">
          <ReferenceId>20085938</ReferenceId>
          <FullCitation>Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="103">
          <ReferenceId>27672108</ReferenceId>
          <FullCitation>Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="104">
          <ReferenceId>28220839</ReferenceId>
          <FullCitation>Milella M, et al. Sci Rep (2017) pmid: 28220839</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="105">
          <ReferenceId>15998902</ReferenceId>
          <FullCitation>Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="106">
          <ReferenceId>19018475</ReferenceId>
          <FullCitation>Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="107">
          <ReferenceId>22160854</ReferenceId>
          <FullCitation>Mason WP, et al. Invest New Drugs (2012) pmid: 22160854</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="108">
          <ReferenceId>20049735</ReferenceId>
          <FullCitation>Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="109">
          <ReferenceId>23881923</ReferenceId>
          <FullCitation>Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="110">
          <ReferenceId>23565244</ReferenceId>
          <FullCitation>Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="111">
          <ReferenceId>26905328</ReferenceId>
          <FullCitation>McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="112">
          <ReferenceId>21468130</ReferenceId>
          <FullCitation>Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="113">
          <ReferenceId>33242536</ReferenceId>
          <FullCitation>Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="114">
          <ReferenceId>33970096</ReferenceId>
          <FullCitation>Pan M, et al. Perm J (2021) pmid: 33970096</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="115">
          <ReferenceId>23810788</ReferenceId>
          <FullCitation>Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="116">
          <ReferenceId>32988624</ReferenceId>
          <FullCitation>Romero I, et al. Gynecol Oncol (2020) pmid: 32988624</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="117">
          <ReferenceId>29165669</ReferenceId>
          <FullCitation>Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="118">
          <ReferenceId>18781191</ReferenceId>
          <FullCitation>Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="119">
          <ReferenceId>18794875</ReferenceId>
          <FullCitation>Orloff MS, et al. Oncogene (2008) pmid: 18794875</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="120">
          <ReferenceId>17167516</ReferenceId>
          <FullCitation>Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="121">
          <ReferenceId>18337605</ReferenceId>
          <FullCitation>Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="122">
          <ReferenceId>20637128</ReferenceId>
          <FullCitation>Liang Z, et al. BMC Cancer (2010) pmid: 20637128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="123">
          <ReferenceId>15920544</ReferenceId>
          <FullCitation>Bhargava R, et al. Mod. Pathol. (2005) pmid: 15920544</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="124">
          <ReferenceId>22490401</ReferenceId>
          <FullCitation>Yang YL, et al. Chin. Med. J. (2012) pmid: 22490401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="125">
          <ReferenceId>8052651</ReferenceId>
          <FullCitation>Nishikawa R, et al. Proc. Natl. Acad. Sci. U.S.A. (1994) pmid: 8052651</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="126">
          <ReferenceId>22385404</ReferenceId>
          <FullCitation>Nedergaard MK, et al. BioDrugs (2012) pmid: 22385404</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="127">
          <ReferenceId>20942962</ReferenceId>
          <FullCitation>Foster JM, et al. World J Surg Oncol (2010) pmid: 20942962</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="128">
          <ReferenceId>18193092</ReferenceId>
          <FullCitation>Cai CQ, et al. Oncogene (2008) pmid: 18193092</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="129">
          <ReferenceId>15735034</ReferenceId>
          <FullCitation>Stabile LP, et al. Cancer Res. (2005) pmid: 15735034</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="130">
          <ReferenceId>17409930</ReferenceId>
          <FullCitation>Zhang W, et al. J Thorac Oncol (2006) pmid: 17409930</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="131">
          <ReferenceId>22258476</ReferenceId>
          <FullCitation>Siegfried JM, et al. J Thorac Oncol (2012) pmid: 22258476</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="132">
          <ReferenceId>24743239</ReferenceId>
          <FullCitation>U M, et al. PLoS Comput. Biol. (2014) pmid: 24743239</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="133">
          <ReferenceId>24894453</ReferenceId>
          <FullCitation>Cho J, et al. Mol. Cancer (2014) pmid: 24894453</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="134">
          <ReferenceId>19726454</ReferenceId>
          <FullCitation>Hama T, et al. Oncologist (2009) pmid: 19726454</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="135">
          <ReferenceId>19671738</ReferenceId>
          <FullCitation>Tam IY, et al. Mol. Cancer Ther. (2009) pmid: 19671738</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="136">
          <ReferenceId>19147750</ReferenceId>
          <FullCitation>Kancha RK, et al. Clin. Cancer Res. (2009) pmid: 19147750</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="137">
          <ReferenceId>16205628</ReferenceId>
          <FullCitation>Chen YR, et al. Oncogene (2006) pmid: 16205628</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="138">
          <ReferenceId>17177598</ReferenceId>
          <FullCitation>Lee JC, et al. PLoS Med. (2006) pmid: 17177598</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="139">
          <ReferenceId>24212795</ReferenceId>
          <FullCitation>Ymer SI, et al. Cancers (Basel) (2011) pmid: 24212795</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="140">
          <ReferenceId>19789313</ReferenceId>
          <FullCitation>Razis E, et al. Clin. Cancer Res. (2009) pmid: 19789313</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="141">
          <ReferenceId>21532887</ReferenceId>
          <FullCitation>Wang H, et al. Neoplasia (2011) pmid: 21532887</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="142">
          <ReferenceId>31290142</ReferenceId>
          <FullCitation>Kim N, et al. Int. J. Cancer (2019) pmid: 31290142</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="143">
          <ReferenceId>32190291</ReferenceId>
          <FullCitation>Sueangoen N, et al. Cell Biosci (2020) pmid: 32190291</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="144">
          <ReferenceId>31585087</ReferenceId>
          <FullCitation>Lundby A, et al. Cell (2019) pmid: 31585087</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="145">
          <ReferenceId>31263031</ReferenceId>
          <FullCitation>Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="146">
          <ReferenceId>26824661</ReferenceId>
          <FullCitation>Ceccarelli M, et al. Cell (2016) pmid: 26824661</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="147">
          <ReferenceId>28472509</ReferenceId>
          <FullCitation>Thomas AA, et al. Neuro-oncology (2017) pmid: 28472509</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="148">
          <ReferenceId>22588883</ReferenceId>
          <FullCitation>Vivanco I, et al. Cancer Discov (2012) pmid: 22588883</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="149">
          <ReferenceId>14583498</ReferenceId>
          <FullCitation>Shinojima N, et al. Cancer Res. (2003) pmid: 14583498</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="150">
          <ReferenceId>15700833</ReferenceId>
          <FullCitation>Nishikawa R, et al. Brain Tumor Pathol (2004) pmid: 15700833</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="151">
          <ReferenceId>16282176</ReferenceId>
          <FullCitation>Mellinghoff IK, et al. N. Engl. J. Med. (2005) pmid: 16282176</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="152">
          <ReferenceId>18507036</ReferenceId>
          <FullCitation>Viana-Pereira M, et al. Anticancer Res. () pmid: 18507036</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="153">
          <ReferenceId>18223223</ReferenceId>
          <FullCitation>Yoshimoto K, et al. Clin. Cancer Res. (2008) pmid: 18223223</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="154">
          <ReferenceId>21455841</ReferenceId>
          <FullCitation>Larysz D, et al. Folia Neuropathol (2011) pmid: 21455841</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="155">
          <ReferenceId>20129251</ReferenceId>
          <FullCitation>Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="156">
          <ReferenceId>22752145</ReferenceId>
          <FullCitation>Lv S, et al. Int. J. Oncol. (2012) pmid: 22752145</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="157">
          <ReferenceId>20702468</ReferenceId>
          <FullCitation>Srividya MR, et al. J. Clin. Pathol. (2010) pmid: 20702468</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="158">
          <ReferenceId>20888234</ReferenceId>
          <FullCitation>Das P, et al. J Clin Neurosci (2011) pmid: 20888234</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="159">
          <ReferenceId>22241957</ReferenceId>
          <FullCitation>Montano N, et al. Neoplasia (2011) pmid: 22241957</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="160">
          <ReferenceId>19204207</ReferenceId>
          <FullCitation>van den Bent MJ, et al. J Clin Oncol (2009) pmid: 19204207</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="161">
          <ReferenceId>15956649</ReferenceId>
          <FullCitation>Haas-Kogan DA, et al. J Natl Cancer Inst (2005) pmid: 15956649</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="162">
          <ReferenceId>18955445</ReferenceId>
          <FullCitation>Brown PD, et al. J Clin Oncol (2008) pmid: 18955445</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="163">
          <ReferenceId>18458820</ReferenceId>
          <FullCitation>Preusser M, et al. J Neurooncol (2008) pmid: 18458820</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="164">
          <ReferenceId>24470557</ReferenceId>
          <FullCitation>Wen PY, et al. Neuro-oncology (2014) pmid: 24470557</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="165">
          <ReferenceId>24352766</ReferenceId>
          <FullCitation>Gallego O, et al. J Neurooncol (2014) pmid: 24352766</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="166">
          <ReferenceId>20510539</ReferenceId>
          <FullCitation>Uhm JH, et al. Int J Radiat Oncol Biol Phys (2011) pmid: 20510539</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="167">
          <ReferenceId>30410775</ReferenceId>
          <FullCitation>Doyle SP, et al. Oxf Med Case Reports (2018) pmid: 30410775</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="168">
          <ReferenceId>23132371</ReferenceId>
          <FullCitation>D'Alessandris QG, et al. Acta Neurochir (Wien) (2013) pmid: 23132371</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="169">
          <ReferenceId>20462843</ReferenceId>
          <FullCitation>Custodio A, et al. Clin Transl Oncol (2010) pmid: 20462843</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="170">
          <ReferenceId>30306271</ReferenceId>
          <FullCitation>D'Alessandris QG, et al. Acta Neurochir (Wien) (2018) pmid: 30306271</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="171">
          <ReferenceId>17255257</ReferenceId>
          <FullCitation>Mellinghoff IK, et al. Clin Cancer Res (2007) pmid: 17255257</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="172">
          <ReferenceId>29492119</ReferenceId>
          <FullCitation>Arif SH, et al. Asian J Neurosurg () pmid: 29492119</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="173">
          <ReferenceId>25140039</ReferenceId>
          <FullCitation>Reardon DA, et al. Neuro-oncology (2015) pmid: 25140039</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="174">
          <ReferenceId>26423602</ReferenceId>
          <FullCitation>Alshami J, et al. Oncotarget (2015) pmid: 26423602</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="175">
          <ReferenceId>28575464</ReferenceId>
          <FullCitation>Sepúlveda-Sánchez JM, et al. Neuro-oncology (2017) pmid: 28575464</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="176">
          <ReferenceId>32923886</ReferenceId>
          <FullCitation>Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="177">
          <ReferenceId>34498213</ReferenceId>
          <FullCitation>Cardona AF, et al. J Neurooncol (2021) pmid: 34498213</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="178">
          <ReferenceId>31769726</ReferenceId>
          <FullCitation>Makhlin I, et al. CNS Oncol (2019) pmid: 31769726</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="179">
          <ReferenceId>32547705</ReferenceId>
          <FullCitation>Chagoya G, et al. Oncotarget (2020) pmid: 32547705</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="180">
          <ReferenceId>33910930</ReferenceId>
          <FullCitation>Gao M, et al. Cancer Res (2021) pmid: 33910930</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="181">
          <ReferenceId>32107712</ReferenceId>
          <FullCitation>Byeon S, et al. Target Oncol (2020) pmid: 32107712</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="182">
          <ReferenceId>32034072</ReferenceId>
          <FullCitation>Reardon DA, et al. Clin Cancer Res (2020) pmid: 32034072</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="183">
          <ReferenceId>28844499</ReferenceId>
          <FullCitation>Weller M, et al. Lancet Oncol (2017) pmid: 28844499</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="184">
          <ReferenceId>22285168</ReferenceId>
          <FullCitation>Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="185">
          <ReferenceId>24263064</ReferenceId>
          <FullCitation>Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="186">
          <ReferenceId>32673682</ReferenceId>
          <FullCitation>Hayashi T, et al. Hum Pathol (2020) pmid: 32673682</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="187">
          <ReferenceId>29780256</ReferenceId>
          <FullCitation>Cao L, et al. Onco Targets Ther (2018) pmid: 29780256</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="188">
          <ReferenceId>21422421</ReferenceId>
          <FullCitation>Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="189">
          <ReferenceId>23816960</ReferenceId>
          <FullCitation>Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="190">
          <ReferenceId>30127622</ReferenceId>
          <FullCitation>Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="191">
          <ReferenceId>27131295</ReferenceId>
          <FullCitation>Frega S, et al. J Thorac Oncol (2016) pmid: 27131295</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="192">
          <ReferenceId>33116645</ReferenceId>
          <FullCitation>Long X, et al. Onco Targets Ther (2020) pmid: 33116645</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="193">
          <ReferenceId>29864379</ReferenceId>
          <FullCitation>Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="194">
          <ReferenceId>25923549</ReferenceId>
          <FullCitation>Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="195">
          <ReferenceId>32749686</ReferenceId>
          <FullCitation>Hong MH, et al. Cancer (2020) pmid: 32749686</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="196">
          <ReferenceId>26462025</ReferenceId>
          <FullCitation>Kim HS, et al. Oncotarget (2015) pmid: 26462025</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="197">
          <ReferenceId>25424851</ReferenceId>
          <FullCitation>Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="198">
          <ReferenceId>32303840</ReferenceId>
          <FullCitation>Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="199">
          <ReferenceId>29734047</ReferenceId>
          <FullCitation>Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="200">
          <ReferenceId>33940677</ReferenceId>
          <FullCitation>Goyal A, et al. World Neurosurg (2021) pmid: 33940677</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="201">
          <ReferenceId>30644426</ReferenceId>
          <FullCitation>Tanaka S, et al. Sci Rep (2019) pmid: 30644426</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="202">
          <ReferenceId>27531351</ReferenceId>
          <FullCitation>Blumenthal DT, et al. J. Neurooncol. (2016) pmid: 27531351</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="203">
          <ReferenceId>17353924</ReferenceId>
          <FullCitation>Franceschi E, et al. Br. J. Cancer (2007) pmid: 17353924</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="204">
          <ReferenceId>23182702</ReferenceId>
          <FullCitation>Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23182702</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="205">
          <ReferenceId>21471286</ReferenceId>
          <FullCitation>Hegi ME, et al. Mol. Cancer Ther. (2011) pmid: 21471286</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="206">
          <ReferenceId>23441167</ReferenceId>
          <FullCitation>Jiang Z, et al. PLoS ONE (2013) pmid: 23441167</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="207">
          <ReferenceId>21048039</ReferenceId>
          <FullCitation>Licitra L, et al. Ann. Oncol. (2011) pmid: 21048039</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="208">
          <ReferenceId>33199443</ReferenceId>
          <FullCitation>Smyth EC, et al. Gut (2021) pmid: 33199443</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="209">
          <ReferenceId>31747009</ReferenceId>
          <FullCitation>Van Den Bent M, et al. Neuro Oncol (2020) pmid: 31747009</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="210">
          <ReferenceId>34185076</ReferenceId>
          <FullCitation>Louis DN, et al. Neuro Oncol (2021) pmid: 34185076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="211">
          <ReferenceId>22015685</ReferenceId>
          <FullCitation>Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="212">
          <ReferenceId>9282118</ReferenceId>
          <FullCitation>Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="213">
          <ReferenceId>7605428</ReferenceId>
          <FullCitation>Kim NW, et al. Science (1994) pmid: 7605428</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="214">
          <ReferenceId>10647931</ReferenceId>
          <FullCitation>Hanahan D, et al. Cell (2000) pmid: 10647931</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="215">
          <ReferenceId>23348503</ReferenceId>
          <FullCitation>Horn S, et al. Science (2013) pmid: 23348503</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="216">
          <ReferenceId>23348506</ReferenceId>
          <FullCitation>Huang FW, et al. Science (2013) pmid: 23348506</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="217">
          <ReferenceId>23887589</ReferenceId>
          <FullCitation>Vinagre J, et al. Nat Commun (2013) pmid: 23887589</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="218">
          <ReferenceId>23530248</ReferenceId>
          <FullCitation>Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="219">
          <ReferenceId>24722048</ReferenceId>
          <FullCitation>Killela PJ, et al. Oncotarget (2014) pmid: 24722048</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="220">
          <ReferenceId>23955565</ReferenceId>
          <FullCitation>Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="221">
          <ReferenceId>23603989</ReferenceId>
          <FullCitation>Liu X, et al. Cell Cycle (2013) pmid: 23603989</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="222">
          <ReferenceId>24154961</ReferenceId>
          <FullCitation>Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="223">
          <ReferenceId>23764841</ReferenceId>
          <FullCitation>Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="224">
          <ReferenceId>24217890</ReferenceId>
          <FullCitation>Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="225">
          <ReferenceId>27245281</ReferenceId>
          <FullCitation>Nat Rev Clin Oncol (2017) pmid: 27245281</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="226">
          <ReferenceId>29249395</ReferenceId>
          <FullCitation>Duperret EK, et al. Mol Ther (2018) pmid: 29249395</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="227">
          <ReferenceId>25467017</ReferenceId>
          <FullCitation>Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="228">
          <ReferenceId>33293629</ReferenceId>
          <FullCitation>Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="229">
          <ReferenceId>26337942</ReferenceId>
          <FullCitation>Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="230">
          <ReferenceId>21081928</ReferenceId>
          <FullCitation>You JF, et al. Br. J. Cancer (2010) pmid: 21081928</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="231">
          <ReferenceId>24623249</ReferenceId>
          <FullCitation>Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="232">
          <ReferenceId>9823339</ReferenceId>
          <FullCitation>Boland CR, et al. Cancer Res. (1998) pmid: 9823339</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="233">
          <ReferenceId>15528785</ReferenceId>
          <FullCitation>Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="234">
          <ReferenceId>20420947</ReferenceId>
          <FullCitation>Boland CR, et al. Gastroenterology (2010) pmid: 20420947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="235">
          <ReferenceId>15331927</ReferenceId>
          <FullCitation>Martinez R, et al. Oncology (2004) pmid: 15331927</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="236">
          <ReferenceId>15672285</ReferenceId>
          <FullCitation>Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="237">
          <ReferenceId>17498554</ReferenceId>
          <FullCitation>Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="238">
          <ReferenceId>12908754</ReferenceId>
          <FullCitation>Szybka M, et al. Clin. Neuropathol. () pmid: 12908754</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="239">
          <ReferenceId>25392179</ReferenceId>
          <FullCitation>Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="240">
          <ReferenceId>26140250</ReferenceId>
          <FullCitation>Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="241">
          <ReferenceId>25949894</ReferenceId>
          <FullCitation>Lal N, et al. Oncoimmunology (2015) pmid: 25949894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="242">
          <ReferenceId>26028255</ReferenceId>
          <FullCitation>Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="243">
          <ReferenceId>8521522</ReferenceId>
          <FullCitation>Quelle DE, et al. Cell (1995) pmid: 8521522</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="244">
          <ReferenceId>15878778</ReferenceId>
          <FullCitation>Mutat. Res. (2005) pmid: 15878778</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="245">
          <ReferenceId>9484839</ReferenceId>
          <FullCitation>Gazzeri S, et al. Oncogene (1998) pmid: 9484839</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="246">
          <ReferenceId>10498883</ReferenceId>
          <FullCitation>Oncogene (1999) pmid: 10498883</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="247">
          <ReferenceId>16869746</ReferenceId>
          <FullCitation>Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="248">
          <ReferenceId>20549699</ReferenceId>
          <FullCitation>Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="249">
          <ReferenceId>10498896</ReferenceId>
          <FullCitation>Ruas M, et al. Oncogene (1999) pmid: 10498896</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="250">
          <ReferenceId>17909018</ReferenceId>
          <FullCitation>Jones R, et al. Cancer Res. (2007) pmid: 17909018</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="251">
          <ReferenceId>18843795</ReferenceId>
          <FullCitation>Haferkamp S, et al. Aging Cell (2008) pmid: 18843795</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="252">
          <ReferenceId>12417717</ReferenceId>
          <FullCitation>Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="253">
          <ReferenceId>11518711</ReferenceId>
          <FullCitation>Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="254">
          <ReferenceId>9324288</ReferenceId>
          <FullCitation>Gombart AF, et al. Leukemia (1997) pmid: 9324288</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="255">
          <ReferenceId>7780957</ReferenceId>
          <FullCitation>Yang R, et al. Cancer Res. (1995) pmid: 7780957</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="256">
          <ReferenceId>8668202</ReferenceId>
          <FullCitation>Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="257">
          <ReferenceId>12606942</ReferenceId>
          <FullCitation>Greenblatt MS, et al. Oncogene (2003) pmid: 12606942</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="258">
          <ReferenceId>10491434</ReferenceId>
          <FullCitation>Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="259">
          <ReferenceId>11255261</ReferenceId>
          <FullCitation>Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="260">
          <ReferenceId>9660926</ReferenceId>
          <FullCitation>Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="261">
          <ReferenceId>19260062</ReferenceId>
          <FullCitation>Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="262">
          <ReferenceId>10719365</ReferenceId>
          <FullCitation>Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="263">
          <ReferenceId>7777061</ReferenceId>
          <FullCitation>Koh J, et al. Nature (1995) pmid: 7777061</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="264">
          <ReferenceId>20340136</ReferenceId>
          <FullCitation>McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="265">
          <ReferenceId>21462282</ReferenceId>
          <FullCitation>Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="266">
          <ReferenceId>905385</ReferenceId>
          <FullCitation>Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="267">
          <ReferenceId>24659262</ReferenceId>
          <FullCitation>Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="268">
          <ReferenceId>23190892</ReferenceId>
          <FullCitation>Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="269">
          <ReferenceId>10389768</ReferenceId>
          <FullCitation>Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="270">
          <ReferenceId>12853981</ReferenceId>
          <FullCitation>Rutter JL, et al. Oncogene (2003) pmid: 12853981</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="271">
          <ReferenceId>18538737</ReferenceId>
          <FullCitation>Itahana K, et al. Cancer Cell (2008) pmid: 18538737</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="272">
          <ReferenceId>10360174</ReferenceId>
          <FullCitation>Zhang Y, et al. Mol. Cell (1999) pmid: 10360174</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="273">
          <ReferenceId>9529249</ReferenceId>
          <FullCitation>Zhang Y, et al. Cell (1998) pmid: 9529249</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="274">
          <ReferenceId>25873077</ReferenceId>
          <FullCitation>Jafri M, et al. Cancer Discov (2015) pmid: 25873077</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="275">
          <ReferenceId>23412337</ReferenceId>
          <FullCitation>Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="276">
          <ReferenceId>16909113</ReferenceId>
          <FullCitation>Weber RG, et al. Oncogene (2007) pmid: 16909113</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="277">
          <ReferenceId>11303791</ReferenceId>
          <FullCitation>Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="278">
          <ReferenceId>11489817</ReferenceId>
          <FullCitation>Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="279">
          <ReferenceId>21713760</ReferenceId>
          <FullCitation>Feng J, et al. Cancer (2012) pmid: 21713760</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="280">
          <ReferenceId>21636552</ReferenceId>
          <FullCitation>Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="281">
          <ReferenceId>21843312</ReferenceId>
          <FullCitation>Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="282">
          <ReferenceId>21278246</ReferenceId>
          <FullCitation>Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="283">
          <ReferenceId>21871868</ReferenceId>
          <FullCitation>Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="284">
          <ReferenceId>22711607</ReferenceId>
          <FullCitation>Cen L, et al. Neuro-oncology (2012) pmid: 22711607</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="285">
          <ReferenceId>23898052</ReferenceId>
          <FullCitation>Logan JE, et al. Anticancer Res. (2013) pmid: 23898052</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="286">
          <ReferenceId>35157829</ReferenceId>
          <FullCitation>Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="287">
          <ReferenceId>28283584</ReferenceId>
          <FullCitation>Elvin JA, et al. Oncologist (2017) pmid: 28283584</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="288">
          <ReferenceId>26715889</ReferenceId>
          <FullCitation>Gao J, et al. Curr Oncol (2015) pmid: 26715889</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="289">
          <ReferenceId>25501126</ReferenceId>
          <FullCitation>DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="290">
          <ReferenceId>25524798</ReferenceId>
          <FullCitation>Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="291">
          <ReferenceId>27542767</ReferenceId>
          <FullCitation>Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="292">
          <ReferenceId>24797823</ReferenceId>
          <FullCitation>Johnson DB, et al. Oncologist (2014) pmid: 24797823</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="293">
          <ReferenceId>22090362</ReferenceId>
          <FullCitation>Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="294">
          <ReferenceId>23569312</ReferenceId>
          <FullCitation>Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="295">
          <ReferenceId>31700061</ReferenceId>
          <FullCitation>Su D, et al. Nat Commun (2019) pmid: 31700061</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="296">
          <ReferenceId>32923894</ReferenceId>
          <FullCitation>Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="297">
          <ReferenceId>21460101</ReferenceId>
          <FullCitation>Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="298">
          <ReferenceId>21725357</ReferenceId>
          <FullCitation>Gamble LD, et al. Oncogene (2012) pmid: 21725357</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="299">
          <ReferenceId>7666917</ReferenceId>
          <FullCitation>Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="300">
          <ReferenceId>20687502</ReferenceId>
          <FullCitation>Adv Exp Med Biol (2010) pmid: 20687502</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="301">
          <ReferenceId>9479083</ReferenceId>
          <FullCitation>Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="302">
          <ReferenceId>29543703</ReferenceId>
          <FullCitation>De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="303">
          <ReferenceId>26892650</ReferenceId>
          <FullCitation>Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="304">
          <ReferenceId>29405243</ReferenceId>
          <FullCitation>Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="305">
          <ReferenceId>8414022</ReferenceId>
          <FullCitation>Kaufman DK, et al. Neurology (1993) pmid: 8414022</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="306">
          <ReferenceId>9622062</ReferenceId>
          <FullCitation>Bahuau M, et al. Cancer Res (1998) pmid: 9622062</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="307">
          <ReferenceId>28699883</ReferenceId>
          <FullCitation>Chan AK, et al. Clin Neuropathol () pmid: 28699883</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="308">
          <ReferenceId>15748635</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="309">
          <ReferenceId>23875803</ReferenceId>
          <FullCitation>Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="310">
          <ReferenceId>12379884</ReferenceId>
          <FullCitation>Pfeifer GP, et al. Oncogene (2002) pmid: 12379884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="311">
          <ReferenceId>25765070</ReferenceId>
          <FullCitation>Rizvi NA, et al. Science (2015) pmid: 25765070</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="312">
          <ReferenceId>24336570</ReferenceId>
          <FullCitation>Johnson BE, et al. Science (2014) pmid: 24336570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="313">
          <ReferenceId>29452419</ReferenceId>
          <FullCitation>Choi S, et al. Neuro-oncology (2018) pmid: 29452419</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="314">
          <ReferenceId>23636398</ReferenceId>
          <FullCitation>Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="315">
          <ReferenceId>23447401</ReferenceId>
          <FullCitation>Briggs S, et al. J. Pathol. (2013) pmid: 23447401</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="316">
          <ReferenceId>24583393</ReferenceId>
          <FullCitation>Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="317">
          <ReferenceId>22810696</ReferenceId>
          <FullCitation>Nature (2012) pmid: 22810696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="318">
          <ReferenceId>25568919</ReferenceId>
          <FullCitation>Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="319">
          <ReferenceId>32322066</ReferenceId>
          <FullCitation>Touat M, et al. Nature (2020) pmid: 32322066</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="320">
          <ReferenceId>30742119</ReferenceId>
          <FullCitation>Zhao J, et al. Nat. Med. (2019) pmid: 30742119</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="321">
          <ReferenceId>30643254</ReferenceId>
          <FullCitation>Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="322">
          <ReferenceId>27001570</ReferenceId>
          <FullCitation>Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="323">
          <ReferenceId>27683556</ReferenceId>
          <FullCitation>Johanns TM, et al. Cancer Discov (2016) pmid: 27683556</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="324">
          <ReferenceId>30073642</ReferenceId>
          <FullCitation>Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="325">
          <ReferenceId>28420421</ReferenceId>
          <FullCitation>Chalmers ZR, et al. Genome Med (2017) pmid: 28420421</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="326">
          <ReferenceId>32386112</ReferenceId>
          <FullCitation>Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="327">
          <ReferenceId>28912153</ReferenceId>
          <FullCitation>Johnson A, et al. Oncologist (2017) pmid: 28912153</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="328">
          <ReferenceId>26699864</ReferenceId>
          <FullCitation>Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="329">
          <ReferenceId>32164609</ReferenceId>
          <FullCitation>Wang L, et al. BMC Cancer (2020) pmid: 32164609</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="330">
          <ReferenceId>28835386</ReferenceId>
          <FullCitation>Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="331">
          <ReferenceId>31405947</ReferenceId>
          <FullCitation>Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="332">
          <ReferenceId>30309915</ReferenceId>
          <FullCitation>Cristescu R, et al. Science (2018) pmid: 30309915</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="333">
          <ReferenceId>30785829</ReferenceId>
          <FullCitation>Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="334">
          <ReferenceId>29658845</ReferenceId>
          <FullCitation>Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="335">
          <ReferenceId>29657128</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="336">
          <ReferenceId>29731394</ReferenceId>
          <FullCitation>Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="337">
          <ReferenceId>33558721</ReferenceId>
          <FullCitation>Rozeman EA, et al. Nat Med (2021) pmid: 33558721</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="338">
          <ReferenceId>32916128</ReferenceId>
          <FullCitation>Sharma P, et al. Cancer Cell (2020) pmid: 32916128</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="339">
          <ReferenceId>24718886</ReferenceId>
          <FullCitation>Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="340">
          <ReferenceId>24739896</ReferenceId>
          <FullCitation>Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="341">
          <ReferenceId>17470858</ReferenceId>
          <FullCitation>Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="342">
          <ReferenceId>23746666</ReferenceId>
          <FullCitation>Vermorken JB, et al. Lancet Oncol (2013) pmid: 23746666</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="343">
          <ReferenceId>19892746</ReferenceId>
          <FullCitation>Wirth LJ, et al. Ann. Oncol. (2010) pmid: 19892746</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="344">
          <ReferenceId>28592616</ReferenceId>
          <FullCitation>Siano M, et al. Oncologist (2017) pmid: 28592616</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="345">
          <ReferenceId>25596660</ReferenceId>
          <FullCitation>Mesía R, et al. Lancet Oncol (2015) pmid: 25596660</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="346">
          <ReferenceId>25596659</ReferenceId>
          <FullCitation>Giralt J, et al. Lancet Oncol (2015) pmid: 25596659</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="347">
          <ReferenceId>27930762</ReferenceId>
          <FullCitation>Siu LL, et al. JAMA Oncol (2016) pmid: 27930762</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="348">
          <ReferenceId>23594787</ReferenceId>
          <FullCitation>Waddell T, et al. Lancet Oncol. (2013) pmid: 23594787</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="349">
          <ReferenceId>24389433</ReferenceId>
          <FullCitation>Crawford J, et al. J Thorac Oncol (2013) pmid: 24389433</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="350">
          <ReferenceId>26094080</ReferenceId>
          <FullCitation>Schuette W, et al. Clin Lung Cancer (2015) pmid: 26094080</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="351">
          <ReferenceId>26540314</ReferenceId>
          <FullCitation>Leone F, et al. Cancer (2016) pmid: 26540314</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="352">
          <ReferenceId>29413685</ReferenceId>
          <FullCitation>Vogel A, et al. Eur J Cancer (2018) pmid: 29413685</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="353">
          <ReferenceId>15210739</ReferenceId>
          <FullCitation>Rowinsky EK, et al. J. Clin. Oncol. (2004) pmid: 15210739</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="354">
          <ReferenceId>26279503</ReferenceId>
          <FullCitation>Whittle JR, et al. J Clin Neurosci (2015) pmid: 26279503</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="355">
          <ReferenceId>20406901</ReferenceId>
          <FullCitation>Hasselbalch B, et al. Neuro-oncology (2010) pmid: 20406901</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="356">
          <ReferenceId>29790314</ReferenceId>
          <FullCitation>Kulason KO, et al. J Exp Ther Oncol (2018) pmid: 29790314</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="357">
          <ReferenceId>35636696</ReferenceId>
          <FullCitation>Kenmotsu H, et al. J Thorac Oncol (2022) pmid: 35636696</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="358">
          <ReferenceId>32139298</ReferenceId>
          <FullCitation>Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="359">
          <ReferenceId>29151359</ReferenceId>
          <FullCitation>Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="360">
          <ReferenceId>31751012</ReferenceId>
          <FullCitation>Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="361">
          <ReferenceId>31825714</ReferenceId>
          <FullCitation>Cho JH, et al. J. Clin. Oncol. (2019) pmid: 31825714</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="362">
          <ReferenceId>33318755</ReferenceId>
          <FullCitation>Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="363">
          <ReferenceId>30255937</ReferenceId>
          <FullCitation>Wang J, et al. Int. J. Cancer (2019) pmid: 30255937</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="364">
          <ReferenceId>19075262</ReferenceId>
          <FullCitation>Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="365">
          <ReferenceId>22946346</ReferenceId>
          <FullCitation>Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="366">
          <ReferenceId>23328813</ReferenceId>
          <FullCitation>Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="367">
          <ReferenceId>29320312</ReferenceId>
          <FullCitation>Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="368">
          <ReferenceId>29998897</ReferenceId>
          <FullCitation>Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="369">
          <ReferenceId>27102076</ReferenceId>
          <FullCitation>Konduri K, et al. Cancer Discov (2016) pmid: 27102076</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="370">
          <ReferenceId>29290255</ReferenceId>
          <FullCitation>Zhu YC, et al. Lung Cancer (2018) pmid: 29290255</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="371">
          <ReferenceId>26398831</ReferenceId>
          <FullCitation>Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="372">
          <ReferenceId>28537764</ReferenceId>
          <FullCitation>Petty RD, et al. J. Clin. Oncol. (2017) pmid: 28537764</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="373">
          <ReferenceId>16809731</ReferenceId>
          <FullCitation>Philip PA, et al. J. Clin. Oncol. (2006) pmid: 16809731</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="374">
          <ReferenceId>32958820</ReferenceId>
          <FullCitation>Xie C, et al. Br J Cancer (2020) pmid: 32958820</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="375">
          <ReferenceId>33026449</ReferenceId>
          <FullCitation>Luo H, et al. JAMA Netw Open (2020) pmid: 33026449</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="376">
          <ReferenceId>22192731</ReferenceId>
          <FullCitation>Lee J, et al. Lancet Oncol. (2012) pmid: 22192731</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="377">
          <ReferenceId>20493771</ReferenceId>
          <FullCitation>Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="378">
          <ReferenceId>31194613</ReferenceId>
          <FullCitation>Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="379">
          <ReferenceId>22056888</ReferenceId>
          <FullCitation>Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="380">
          <ReferenceId>14638850</ReferenceId>
          <FullCitation>Rich JN, et al. J Clin Oncol (2004) pmid: 14638850</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="381">
          <ReferenceId>16467100</ReferenceId>
          <FullCitation>Reardon DA, et al. Clin Cancer Res (2006) pmid: 16467100</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="382">
          <ReferenceId>27232884</ReferenceId>
          <FullCitation>Brown N, et al. PLoS One (2016) pmid: 27232884</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="383">
          <ReferenceId>24950987</ReferenceId>
          <FullCitation>Dutton SJ, et al. Lancet Oncol. (2014) pmid: 24950987</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="384">
          <ReferenceId>22370314</ReferenceId>
          <FullCitation>Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="385">
          <ReferenceId>20573926</ReferenceId>
          <FullCitation>Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="386">
          <ReferenceId>20022809</ReferenceId>
          <FullCitation>Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="387">
          <ReferenceId>19692680</ReferenceId>
          <FullCitation>Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="388">
          <ReferenceId>25329826</ReferenceId>
          <FullCitation>Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826</FullCitation>
          <Include>true</Include>
        </Reference>
        <Reference number="389">
          <ReferenceId>25546556</ReferenceId>
          <FullCitation>Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556</FullCitation>
          <Include>true</Include>
        </Reference>
      </References>
      <Signatures>
        <Signature>
          <ServerTime>2023-06-06 20:44:37</ServerTime>
          <OpName>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</OpName>
          <Text>Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director</Text>
        </Signature>
      </Signatures>
      <reportProperties>
        <reportProperty identifier="QualityControlMetrics" key="MedianCoverageValue">
          <value>816x</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorMutationBurdenScore">
          <value>2 Muts/Mb</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="MicrosatelliteStatusScore">
          <value>0 fraction-unstable-loci</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="LossOfHeterozygosityScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="BloodTumorMutationalBurdenScore">
          <value>Units Not Reported</value>
        </reportProperty>
        <reportProperty identifier="AdditionalFindings" key="TumorFractionScore">
          <value>Units Not Reported</value>
        </reportProperty>
      </reportProperties>
      <comments />
      <AAC>
        <Amendmends />
      </AAC>
    </FinalReport>
    <variant-report xmlns="http://foundationmedicine.com/compbio/variant-report-external" disease="BRAIN" disease-ontology="Brain glioblastoma (GBM)" flowcell-analysis="2000029373" gender="female" pathology-diagnosis="Glioblastoma" percent-tumor-nuclei="50" pipeline-version="v3.22.0" purity-assessment="76.52" specimen="ORD-1640275-01*US1564901.01" study="CLINICAL-F1CDx v2" test-request="ORD-1640275-01" test-type="FoundationOneDx" tissue-of-origin="Brain" xsi:schemaLocation="http://foundationmedicine.com/compbio/variant-report-external http://integration.foundationmedicine.com/reporting/variant-report-external-2.2.xsd">
      <samples>
        <sample bait-set="DX2" mean-exon-depth="865.94" name="SQ-US1564901.01-1" nucleic-acid-type="DNA" />
      </samples>
      <quality-control status="Pass" />
      <short-variants>
        <short-variant allele-fraction="0.3341" cds-effect="482G&gt;A" depth="826" equivocal="false" functional-effect="missense" gene="NTRK1" percent-reads="33.41" position="chr1:156837949" protein-effect="R161H" status="unknown" strand="+" transcript="NM_002529">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.2714" cds-effect="661G&gt;A" depth="70" equivocal="false" functional-effect="missense" gene="GATA6" percent-reads="27.14" position="chr18:19751766" protein-effect="A221T" status="unknown" strand="+" transcript="NM_005257">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6142" cds-effect="2234C&gt;T" depth="661" equivocal="false" functional-effect="missense" gene="JAK3" percent-reads="61.42" position="chr19:17945496" protein-effect="P745L" status="unknown" strand="-" transcript="NM_000215">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.6466" cds-effect="682G&gt;A" depth="846" equivocal="false" functional-effect="missense" gene="BRD4" percent-reads="64.66" position="chr19:15376332" protein-effect="V228I" status="unknown" strand="-" transcript="NM_014299">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.1996" cds-effect="3071A&gt;T" depth="506" equivocal="false" functional-effect="missense" gene="TEK" percent-reads="19.96" position="chr9:27218783" protein-effect="Y1024F" status="unknown" strand="+" transcript="NM_000459">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5956" cds-effect="634+1G&gt;A" depth="549" equivocal="false" functional-effect="splice" gene="PTEN" percent-reads="59.56" position="chr10:89712017" protein-effect="splice site 634+1G&gt;A" status="likely" strand="+" transcript="NM_000314">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5188" cds-effect="550G&gt;T" depth="133" equivocal="false" functional-effect="missense" gene="MYCN" percent-reads="51.88" position="chr2:16082736" protein-effect="A184S" status="unknown" strand="+" transcript="NM_005378">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.016" cds-effect="1793G&gt;T" depth="9827" equivocal="false" functional-effect="missense" gene="EGFR" percent-reads="1.6" position="chr7:55233043" protein-effect="G598V" status="known" strand="+" subclonal="true" transcript="NM_005228">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4745" cds-effect="6325G&gt;A" depth="881" equivocal="false" functional-effect="missense" gene="BRCA2" percent-reads="47.45" position="chr13:32914817" protein-effect="V2109I" status="unknown" strand="+" transcript="NM_000059">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3841" cds-effect="-146C&gt;T" depth="151" equivocal="false" functional-effect="promoter" gene="TERT" percent-reads="38.41" position="chr5:1295250" protein-effect="promoter -146C&gt;T" status="known" strand="-" transcript="NM_198253">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4863" cds-effect="385G&gt;C" depth="911" equivocal="false" functional-effect="missense" gene="APC" percent-reads="48.63" position="chr5:112103050" protein-effect="E129Q" status="unknown" strand="+" transcript="NM_000038">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.5267" cds-effect="2701C&gt;G" depth="562" equivocal="false" functional-effect="missense" gene="ABL1" percent-reads="52.67" position="chr9:133760378" protein-effect="P901A" status="unknown" strand="+" transcript="NM_005157">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.4725" cds-effect="1370_1372delAGG" depth="563" equivocal="false" functional-effect="nonframeshift" gene="DAXX" percent-reads="47.25" position="chr6:33287880" protein-effect="E457del" status="unknown" strand="-" transcript="NM_001350">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3669" cds-effect="814C&gt;A" depth="387" equivocal="false" functional-effect="missense" gene="MEF2B" percent-reads="36.69" position="chr19:19257149" protein-effect="P272T" status="unknown" strand="-" transcript="NM_001145785">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
        <short-variant allele-fraction="0.3464" cds-effect="16391C&gt;T" depth="713" equivocal="false" functional-effect="missense" gene="MLL2" percent-reads="34.64" position="chr12:49416084" protein-effect="T5464M" status="unknown" strand="-" transcript="NM_003482">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </short-variant>
      </short-variants>
      <copy-number-alterations>
        <copy-number-alteration copy-number="0" equivocal="false" gene="MTAP" number-of-exons="8 of 8" position="chr9:21802699-21862058" ratio="0.22" status="known" type="loss">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="0" equivocal="false" gene="CDKN2A" number-of-exons="5 of 5" position="chr9:21968169-21994453" ratio="0.22" status="known" type="loss">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="0" equivocal="false" gene="CDKN2B" number-of-exons="5 of 5" position="chr9:22002170-22010784" ratio="0.22" status="known" type="loss">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </copy-number-alteration>
        <copy-number-alteration copy-number="50" equivocal="false" gene="EGFR" number-of-exons="30 of 30" position="chr7:55086949-55273310" ratio="16.97" status="known" type="amplification">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </copy-number-alteration>
      </copy-number-alterations>
      <rearrangements>
        <rearrangement allele-fraction="0.0321" description="EGFR(NM_005228) deletion intron 1 - intron 7" equivocal="false" in-frame="Yes" other-gene="EGFR" percent-reads="3.21" pos1="chr7:55222597" pos2="chr7:55090010" status="known" supporting-read-pairs="794" targeted-gene="EGFR" type="deletion">
          <dna-evidence sample="SQ-US1564901.01-1" />
        </rearrangement>
      </rearrangements>
      <biomarkers>
        <microsatellite-instability status="MSS" />
        <tumor-mutation-burden score="2.41" status="low" unit="mutations-per-megabase" />
      </biomarkers>
      <non-human-content />
    </variant-report>
  </rr:ResultsPayload>
</rr:ResultsReport>
